Professor Philip Barter

Magdas A; Ding J; McClelland RL; Allison MA; Barter PJ; Rye KA; Ong KL, 2019, 'The relationship of circulating fibroblast growth factor 21 levels with pericardial fat: The Multi-Ethnic Study of Atherosclerosis', Scientific Reports, vol. 9, http://dx.doi.org/10.1038/s41598-019-52933-9

Wu BJ; Li Y; Ong KL; Sun Y; Johns D; Barter PJ; Rye KA, 2019, 'The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits', Scientific Reports, vol. 9, http://dx.doi.org/10.1038/s41598-019-52510-0

Neeland IJ; Ross R; Després JP; Matsuzawa Y; Yamashita S; Shai I; Seidell J; Magni P; Santos RD; Arsenault B, 2019, 'Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement', The Lancet Diabetes and Endocrinology, vol. 7, pp. 715 - 725, http://dx.doi.org/10.1016/S2213-8587(19)30084-1

Fruchart JC; Santos RD; Yamashita S; Libby P; Aikawa M; Plutzky J; Pradhan A; Ridker P; Aguilar-Salinas C; Al Rasadi K, 2019, 'Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?', Diabetes and Metabolic Syndrome: Clinical Research and Reviews, vol. 13, pp. 2723 - 2725, http://dx.doi.org/10.1016/j.dsx.2019.05.034

Hou L; Tang S; Wu BJ; Ong KL; Westerterp M; Barter PJ; Cochran BJ; Tabet F; Rye KA, 2019, 'Apolipoprotein A-l improves pancreatic β-cell function independent of the ATP-binding cassette transporters ABCA1 and ABCG1', FASEB Journal, vol. 33, pp. 8479 - 8489, http://dx.doi.org/10.1096/fj.201802512RR

Fruchart JC; Santos RD; Aguilar-Salinas C; Aikawa M; Al Rasadi K; Amarenco P; Barter PJ; Ceska R; Corsini A; Després JP, 2019, 'The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: Conceptual framework and therapeutic potential', Cardiovascular Diabetology, vol. 18, http://dx.doi.org/10.1186/s12933-019-0864-7

Wu BJ; Sun Y; Ong KL; Li Y; Tang S; Barter PJ; Rye KA, 2019, 'Apolipoprotein A-I Protects Against Pregnancy-Induced Insulin Resistance in Rats', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 39, pp. 1160 - 1171, http://dx.doi.org/10.1161/ATVBAHA.118.312282

Scherer DJ; Nelson AJ; O'Brien R; Kostner KM; Hare DL; Colquhoun DM; Barter PJ; Aylward P; Nicholls SJ; Watts GF, 2019, 'Status of PCSK9 Monoclonal Antibodies in Australia', Heart Lung and Circulation, vol. 28, pp. 1571 - 1579, http://dx.doi.org/10.1016/j.hlc.2019.04.014

Ong KL; McClelland RL; Allison MA; Kokkinos J; Wu BJ; Barter PJ; Rye KA, 2019, 'Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: The Multi-Ethnic Study of Atherosclerosis', Atherosclerosis, vol. 281, pp. 200 - 206, http://dx.doi.org/10.1016/j.atherosclerosis.2018.10.011

Barter P; Genest J, 2019, 'HDL cholesterol and ASCVD risk stratification: A debate', Atherosclerosis, vol. 283, pp. 7 - 12, http://dx.doi.org/10.1016/j.atherosclerosis.2019.01.001

Tang S; Tabet F; Cochran BJ; Cuesta Torres LF; Wu BJ; Barter PJ; Rye KA, 2019, 'Apolipoprotein A-I enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle', Scientific Reports, vol. 9, http://dx.doi.org/10.1038/s41598-018-38014-3

Ong KL; Hui N; Januszewski AS; Kaakoush NO; Xu A; Fayyad R; DeMicco DA; Jenkins AJ; Keech AC; Waters DD, 2019, 'High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study)', Metabolism: Clinical and Experimental, vol. 93, pp. 93 - 99, http://dx.doi.org/10.1016/j.metabol.2018.11.006

Palmer MK; Barter PJ; Lundman P; Nicholls SJ; Toth PP; Karlson BW, 2019, 'Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis', Clinical Biochemistry, vol. 64, pp. 24 - 29, http://dx.doi.org/10.1016/j.clinbiochem.2018.10.011

Alshamiri M; Ghanaim MMA; Barter P; Chang KC; Li JJ; Matawaran BJ; Santoso A; Shaheen S; Suastika K; Thongtang N, 2018, 'Expert opinion on the applicability of dyslipidemia guidelines in Asia and the middle east', International Journal of General Medicine, vol. 11, pp. 313 - 322, http://dx.doi.org/10.2147/IJGM.S160555

Barter PJ, 2018, 'High- versus low-dose statin: Effects on cardiovascular events and all-cause death', Circulation, vol. 137, pp. 2013 - 2015, http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034407

Vallejo-Vaz AJ; Fayyad R; Matthijs Boekholdt S; Kees Hovingh G; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK, 2018, 'Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial', Circulation, vol. 138, pp. 770 - 781, http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032318

Nicholls SJ; Lincoff AM; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D, 2018, 'Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial', Clinical Cardiology, vol. 41, pp. 1281 - 1288, http://dx.doi.org/10.1002/clc.23055

Barter PJ; Cochran BJ; Rye KA, 2018, 'CETP inhibition, statins and diabetes', Atherosclerosis, vol. 278, pp. 143 - 146, http://dx.doi.org/10.1016/j.atherosclerosis.2018.09.033

Shapiro JD; Thavaneswaran S; Underhill CR; Robledo KP; Karapetis CS; Day FL; Nott LM; Jefford M; Chantrill LA; Pavlakis N, 2018, 'Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study', Clinical Colorectal Cancer, vol. 17, pp. 313 - 319, http://dx.doi.org/10.1016/j.clcc.2018.06.002

Tarnow-Mordi W; Morris J; Kirby A; Robledo K; Askie L; Brown R; Evans N; Finlayson S; Fogarty M; Gebski V, 2018, 'Delayed Versus Immediate Cord Clamping in Preterm Infants', Obstetrical and Gynecological Survey, vol. 73, pp. 265 - 266, http://dx.doi.org/10.1097/01.ogx.0000534708.24689.e0

Lee CK; Hudson M; Simes J; Ribi K; Bernhard J; Coates AS, 2018, 'When do patient reported quality of life indicators become prognostic in breast cancer?', Health and Quality of Life Outcomes, vol. 16, http://dx.doi.org/10.1186/s12955-017-0834-2

Jonker DJ; Nott L; Yoshino T; Gill S; Shapiro J; Ohtsu A; Zalcberg J; Vickers MM; Wei AC; Gao Y, 2018, 'Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 263 - 270, http://dx.doi.org/10.1016/S2468-1253(18)30009-8

Barter PJ; Waters DD, 2018, 'Variations in time to benefit among clinical trials of cholesterol-lowering drugs', Journal of Clinical Lipidology, vol. 12, pp. 857 - 862, http://dx.doi.org/10.1016/j.jacl.2018.04.006

Shrestha S; Wu BJ; Guiney L; Barter PJ; Rye KA, 2018, 'Cholesteryl ester transfer protein and its inhibitors', Journal of Lipid Research, vol. 59, pp. 772 - 783, http://dx.doi.org/10.1194/jlr.R082735

Karlson BW; Nicholls SJ; Lundman P; Barter PJ; Palmer MK, 2018, 'Modeling statin-induced reductions of cardiovascular events in primary prevention: A VOYAGER meta-analysis', Cardiology (Switzerland), vol. 140, pp. 30 - 34, http://dx.doi.org/10.1159/000488311

Schwartz GG; Ballantyne CM; Barter PJ; Kallend D; Leiter LA; Leitersdorf E; McMurray JJV; Nicholls SJ; Olsson AG; Shah PK, 2018, 'Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: Analysis of the dal-outcomes randomized clinical trial', JAMA Cardiology, vol. 3, pp. 164 - 168, http://dx.doi.org/10.1001/jamacardio.2017.3833

Hui TH; McClelland RL; Allison MA; Rodriguez CJ; Kronmal RA; Heckbert SR; Michos ED; Barter PJ; Rye KA; Ong KL, 2018, 'The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis', Atherosclerosis, vol. 269, pp. 86 - 91, http://dx.doi.org/10.1016/j.atherosclerosis.2017.12.026

Barter PJ; Rye KA, 2018, 'Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk', Cardiology Clinics, vol. 36, pp. 299 - 310, http://dx.doi.org/10.1016/j.ccl.2017.12.011

Ong KL; Waters DD; Fayyad R; Vogt L; Melamed S; DeMicco DA; Rye KA; Barter PJ, 2018, 'Relationship of high-density lipoprotein cholesterol with renal function in patients treated with atorvastatin', Journal of the American Heart Association, vol. 7, http://dx.doi.org/10.1161/JAHA.117.007387

Waters DD; Bangalore S; Fayyad R; DeMicco DA; Laskey R; Melamed S; Barter PJ, 2018, 'Visit-to-visit variability of lipid measurements as predictors of cardiovascular events', Journal of Clinical Lipidology, vol. 12, pp. 356 - 366, http://dx.doi.org/10.1016/j.jacl.2017.12.003

Choteau SA; Cuesta Torres LF; Barraclough JY; Elder AMM; Martínez GJ; Chen Fan WY; Shrestha S; Ong KL; Barter PJ; Celermajer DS, 2018, 'Transcoronary gradients of HDL-associated MicroRNAs in unstable coronary artery disease', International Journal of Cardiology, vol. 253, pp. 138 - 144, http://dx.doi.org/10.1016/j.ijcard.2017.09.190

Rosenson RS; Brewer HB; Barter PJ; Björkegren JLM; Chapman MJ; Gaudet D; Kim DS; Niesor E; Rye KA; Sacks FM, 2018, 'HDL and atherosclerotic cardiovascular disease: Genetic insights into complex biology', Nature Reviews Cardiology, vol. 15, pp. 9 - 19, http://dx.doi.org/10.1038/nrcardio.2017.115

Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA, 2018, 'Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascu', Journal of Clinical Lipidology, vol. 12, pp. 130 - 136, http://dx.doi.org/10.1016/j.jacl.2017.10.001

Field KM; Fitt G; Rosenthal MA; Simes J; Nowak AK; Barnes EH; Sawkins K; Goh C; Moffat BA; Salinas S, 2018, 'Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial', Asia-Pacific Journal of Clinical Oncology, vol. 14, pp. e359 - e365, http://dx.doi.org/10.1111/ajco.12806

Rankin NM; Lai M; Miller D; Beale P; Spigelman A; Prest G; Turley K; Simes J, 2018, 'Cancer multidisciplinary team meetings in practice: Results from a multi-institutional quantitative survey and implications for policy change', Asia-Pacific Journal of Clinical Oncology, vol. 14, pp. 74 - 83, http://dx.doi.org/10.1111/ajco.12765

Martin AJ; Gibbs E; Sjoquist K; Pavlakis N; Simes J; Price T; Shannon J; Gill S; Jain V; Liu G, 2018, 'Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma', Gastric Cancer, vol. 21, pp. 473 - 480, http://dx.doi.org/10.1007/s10120-017-0754-1

Bowman L; Hopewell JC; Chen F; Wallendszus K; Stevens W; Collins R; Wiviott SD; Cannon CP; Braunwald E; Sammons E, 2017, 'Effects of anacetrapib in patients with atherosclerotic vascular disease', New England Journal of Medicine, vol. 377, pp. 1217 - 1227, http://dx.doi.org/10.1056/NEJMoa1706444

Cochran BJ; Hou L; Manavalan APC; Moore BM; Tabet F; Sultana A; Cuesta Torres L; Tang S; Shrestha S; Senanayake P, 2017, 'Erratum. Impact of Perturbed Pancreatic β-Cell Cholesterol Homeostasis on Adipose Tissue and Skeletal Muscle Metabolism. Diabetes 2016;65:3610-3620.', Diabetes, vol. 66, pp. 560, http://dx.doi.org/10.2337/db17-er02b

Bowman L; Chen F; Sammons E; Hopewell JC; Wallendszus K; Stevens W; Valdes-Marquez E; Wiviott S; Cannon CP; Braunwald E, 2017, 'Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with est', American Heart Journal, vol. 187, pp. 182 - 190, http://dx.doi.org/10.1016/j.ahj.2017.02.021

Wetzig N; Gill PG; Espinoza D; Mister R; Stockler MR; Gebski VJ; Ung OA; Campbell I; Simes J, 2017, 'Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? Five-Year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial: Assessment and Incidence of True Lymph', Annals of Surgical Oncology, vol. 24, pp. 1064 - 1070, http://dx.doi.org/10.1245/s10434-016-5669-2

Leong T; Smithers BM; Haustermans K; Michael M; Gebski V; Miller D; Zalcberg J; Boussioutas A; Findlay M; O’Connell RL, 2017, 'TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Tr', Annals of Surgical Oncology, vol. 24, pp. 2252 - 2258, http://dx.doi.org/10.1245/s10434-017-5830-6

Stewart RAH; Colquhoun DM; Marschner SL; Kirby AC; Simes J; Nestel PJ; Glozier N; O'Neil A; Oldenburg B; White HD, 2017, 'Persistent psychological distress and mortality in patients with stable coronary artery disease', Heart, vol. 103, pp. 1860 - 1866, http://dx.doi.org/10.1136/heartjnl-2016-311097

Driscoll A; Barnes EH; Blankenberg S; Colquhoun DM; Hunt D; Nestel PJ; Stewart RA; West MJ; White HD; Simes J, 2017, 'Predictors of incident heart failure in patients after an acute coronary syndrome: The LIPID heart failure risk-prediction model', International Journal of Cardiology, vol. 248, pp. 361 - 368, http://dx.doi.org/10.1016/j.ijcard.2017.06.098

Hovey EJ; Field KM; Rosenthal MA; Barnes EH; Cher L; Nowak AK; Wheeler H; Sawkins K; Livingstone A; Phal P, 2017, 'Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: An exploratory randomized phase II trial', Neuro-Oncology Practice, vol. 4, pp. 171 - 181, http://dx.doi.org/10.1093/nop/npw025

Bagdade J; Barter P; Quiroga C; Alaupovic P, 2017, 'Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial)', American Journal of Cardiology, vol. 119, pp. 1753 - 1756, http://dx.doi.org/10.1016/j.amjcard.2017.02.049

Chung RWS; Wang Z; Bursill CA; Wu BJ; Barter PJ; Rye KA, 2017, 'Effect of long-term dietary sphingomyelin supplementation on atherosclerosis in mice', PLoS ONE, vol. 12, http://dx.doi.org/10.1371/journal.pone.0189523

Wu BJ; Li Y; Ong KL; Sun Y; Shrestha S; Hou L; Johns D; Barter PJ; Rye KA, 2017, 'Reduction of in-stent restenosis by cholesteryl ester transfer protein inhibition', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 37, pp. 2333 - 2341, http://dx.doi.org/10.1161/ATVBAHA.117.310051

van den Bent M; Gan HK; Lassman AB; Kumthekar P; Merrell R; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP, 2017, 'Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study', Cancer Chemotherapy and Pharmacology, vol. 80, pp. 1209 - 1217, http://dx.doi.org/10.1007/s00280-017-3451-1

Barter PJ; Rye KA, 2017, 'HDL cholesterol concentration or HDL function: Which matters?', European Heart Journal, vol. 38, pp. 2487 - 2489, http://dx.doi.org/10.1093/eurheartj/ehx274

van Capelleveen JC; Bochem AE; Boekholdt SM; Mora S; Hoogeveen RC; Ballantyne CM; Ridker PM; Sun W; Barter PJ; Tall AR, 2017, 'Association of high-density lipoprotein-cholesterol versus apolipoprotein A-I with risk of coronary heart disease: The European prospective investigation into cancer-norfolk prospective population stu', Journal of the American Heart Association, vol. 6, http://dx.doi.org/10.1161/JAHA.117.006636

Won KB; Hur SH; Nam CW; Ann SH; Park GM; Lee SG; Kim HE; Cho YK; Yoon HJ; Park HS, 2017, 'Evaluation of the impact of statin therapy on the obesity paradox in patients with acute myocardial infarction', Medicine (United States), vol. 96, http://dx.doi.org/10.1097/MD.0000000000007180

Karlson BW; Palmer MK; Nicholls SJ; Barter PJ; Lundman P, 2017, 'Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database', Atherosclerosis, vol. 265, pp. 54 - 59, http://dx.doi.org/10.1016/j.atherosclerosis.2017.08.014

Ong KL; O'Connell R; Januszewski AS; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Scott RS; Taskinen MR; Waldman B, 2017, 'Baseline circulating FGF21 concentrations and increase after fenofibrate treatment predict more rapid glycemic progression in type 2 diabetes: Results from the FIELD study', Clinical Chemistry, vol. 63, pp. 1261 - 1270, http://dx.doi.org/10.1373/clinchem.2016.270876

Field KM; Phal PM; Fitt G; Goh C; Nowak AK; Rosenthal MA; Simes J; Barnes EH; Sawkins K; Cher LM, 2017, 'The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET)', Cancer, vol. 123, pp. 3576 - 3582, http://dx.doi.org/10.1002/cncr.30838

Cochran BJ; Ryder WJ; Parmar A; Klaeser K; Reilhac A; Angelis GI; Meikle SR; Barter PJ; Rye KA, 2017, 'Determining glucose metabolism kinetics using ¹⁸F-FDG micro-PET/CT', Journal of Visualized Experiments, vol. 2017, http://dx.doi.org/10.3791/55184

Puri R; Ballantyne CM; Hoogeveen RC; Shao M; Barter P; Libby P; Chapman MJ; Erbel R; Arsenault BJ; Raichlen JS, 2017, 'Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN', Atherosclerosis, vol. 263, pp. 137 - 144, http://dx.doi.org/10.1016/j.atherosclerosis.2017.06.026

Field KM; King MT; Simes J; Espinoza D; Barnes EH; Sawkins K; Rosenthal MA; Cher L; Hovey E; Wheeler H, 2017, 'Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma', Journal of Neuro-Oncology, vol. 133, pp. 623 - 631, http://dx.doi.org/10.1007/s11060-017-2479-8

Lincoff AM; Nicholls SJ; Riesmeyer JS; Barter PJ; Brewer HB; Fox KAA; Gibson CM; Granger C; Menon V; Montalescot G, 2017, 'Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease', New England Journal of Medicine, vol. 376, pp. 1933 - 1942, http://dx.doi.org/10.1056/NEJMoa1609581

Pandzic E; Gelissen IC; Whan R; Barter PJ; Sviridov D; Gaus K; Rye KA; Cochran BJ, 2017, 'The ATP binding cassette transporter, ABCG1, localizes to cortical actin filaments', Scientific Reports, vol. 7, http://dx.doi.org/10.1038/srep42025

Pitts R; Gunzburger E; Ballantyne CM; Barter PJ; Kallend D; Leiter LA; Leitersdorf E; Nicholls SJ; Shah PK; Tardif JC, 2017, 'Aldosterone does not predict cardiovascular events following acute coronary syndrome in patients initially without heart failure', Journal of the American Heart Association, vol. 6, http://dx.doi.org/10.1161/JAHA.116.004119

Hague WE; Simes J; Kirby A; Keech AC; White HD; Hunt D; Nestel PJ; Colquhoun DM; Pater H; Stewart RA, 2016, 'Long-term effectiveness and safety of pravastatin in patients with coronary heart disease', Circulation, vol. 133, pp. 1851 - 1860, http://dx.doi.org/10.1161/CIRCULATIONAHA.115.018580

Reith C; Blackwell L; Emberson J; Mihaylova B; Armitage J; Fulcher J; Keech A; Simes J; Baigent C; Collins R, 2016, 'Protocol for analyses of adverse event data from randomized controlled trials of statin therapy', American Heart Journal, vol. 176, pp. 63 - 69, http://dx.doi.org/10.1016/j.ahj.2016.01.016

Liu G; Tu D; Lewis M; Cheng D; Sullivan LA; Chen Z; Morgen E; Simes J; Price TJ; Tebbutt NC, 2016, 'Fc-g receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer', Clinical Cancer Research, vol. 22, pp. 2435 - 2444, http://dx.doi.org/10.1158/1078-0432.CCR-15-0414

Herrington WG; Emberson J; Mihaylova B; Blackwell L; Reith C; Solbu MD; Mark PB; Fellström B; Jardine AG; Wanner C, 2016, 'Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials', The Lancet Diabetes and Endocrinology, vol. 4, pp. 829 - 839, http://dx.doi.org/10.1016/S2213-8587(16)30156-5

Al Rasadi K; Almahmeed W; AlHabib KF; Abifadel M; Farhan HA; AlSifri S; Jambart S; Zubaid M; Awan Z; Al-Waili K, 2016, 'Dyslipidaemia in the Middle East: Current status and a call for action', Atherosclerosis, vol. 252, pp. 182 - 187, http://dx.doi.org/10.1016/j.atherosclerosis.2016.07.925

Karlson BW; Wiklund O; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2016, 'Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: Results from VOYAGER', European Heart Journal - Cardiovascular Pharmacotherapy, vol. 2, pp. 212 - 217, http://dx.doi.org/10.1093/ehjcvp/pvw006

Pitts R; Gunzburger E; Ballantyne CM; Barter PJ; Kallend D; Leiter LA; Leitersdorf E; McMurray JJV; Nicholls SJ; Niesor EJ, 2016, 'Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein', Journal of the American College of Cardiology, vol. 68, pp. 2488 - 2490, http://dx.doi.org/10.1016/j.jacc.2016.09.932

Barter P; Janus E; Matsuzawa Y; Su TC; Sy R; Tomlinson B; Yamashita S; Yeh HL, 2016, 'Professor Philip Yu-An Ding 1949-2015', Journal of atherosclerosis and thrombosis, vol. 23, pp. 1367, http://dx.doi.org/10.5551/jat.MR001

Collins R; Reith C; Emberson J; Armitage J; Baigent C; Blackwell L; Blumenthal R; Danesh J; Smith GD; DeMets D, 2016, 'Interpretation of the evidence for the efficacy and safety of statin therapy', The Lancet, vol. 388, pp. 2532 - 2561, http://dx.doi.org/10.1016/S0140-6736(16)31357-5

Alshehry ZH; Mundra PA; Barlow CK; Mellett NA; Wong G; McConville MJ; Simes J; Tonkin AM; Sullivan DR; Barnes EH, 2016, 'Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus', Circulation, vol. 134, pp. 1637 - 1650, http://dx.doi.org/10.1161/CIRCULATIONAHA.116.023233

Cochran BJ; Hou L; Manavalan APC; Moore BM; Tabet F; Sultana A; Torres LC; Tang S; Shrestha S; Senanayake P, 2016, 'Impact of perturbed pancreatic β-cell cholesterol homeostasis on adipose tissue and skeletal muscle metabolism', Diabetes, vol. 65, pp. 3610 - 3620, http://dx.doi.org/10.2337/db16-0668

Al Sayed N; Al Waili K; Alawadi F; Al-Ghamdi S; Al Mahmeed W; Al-Nouri F; Al Rukhaimi M; Al-Rasadi K; Awan Z; Farghaly M, 2016, 'Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East', International Journal of Cardiology, vol. 225, pp. 268 - 283, http://dx.doi.org/10.1016/j.ijcard.2016.09.081

Lee CK; Davies L; Gebski VJ; Lord SJ; Di Leo A; Johnston S; Geyer C; Cameron D; Press MF; Ellis C, 2016, 'Serum human epidermal growth factor 2 extracellular domain as a predictive biomarker for lapatinib treatment efficacy in patients with advanced breast cancer', Journal of Clinical Oncology, vol. 34, pp. 936 - 944, http://dx.doi.org/10.1200/JCO.2015.62.4767

Pavlakis N; Sjoquist KM; Martin AJ; Tsobanis E; Yip S; Kang YK; Bang YJ; Alcindor T; O'Callaghan CJ; Burnell MJ, 2016, 'Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II Trial', Journal of Clinical Oncology, vol. 34, pp. 2728 - 2735, http://dx.doi.org/10.1200/JCO.2015.65.1901

Segelov E; Thavaneswaran S; Waring PM; Desai J; Robledo KP; Gebski VJ; Elez E; Nott LM; Karapetis CS; Lunke S, 2016, 'Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian gastro-intestinal trials group ICECREAM study', Journal of Clinical Oncology, vol. 34, pp. 2258 - 2264, http://dx.doi.org/10.1200/JCO.2015.65.6843

Ferraro D; Goldstein D; O'Connell RL; Zalcberg JR; Sjoquist KM; Tebbutt NC; Grimison P; McLachlan S; Lipton LL; Vasey P, 2016, 'TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer', Cancer Chemotherapy and Pharmacology, vol. 78, pp. 361 - 367, http://dx.doi.org/10.1007/s00280-016-3089-4

Cochran BJ; Ryder WJ; Parmar A; Tang S; Reilhac A; Arthur A; Charil A; Hamze H; Barter PJ; Kritharides L, 2016, 'In vivo PET imaging with [¹⁸F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes', Diabetologia, vol. 59, pp. 1977 - 1984, http://dx.doi.org/10.1007/s00125-016-3993-5

Geronimo FRB; Barter PJ; Rye KA; Heather AK; Shearston KD; Rodgers KJ, 2016, 'Plaque stabilizing effects of apolipoprotein A-IV', Atherosclerosis, vol. 251, pp. 39 - 46, http://dx.doi.org/10.1016/j.atherosclerosis.2016.04.019

Santos RD; Gidding SS; Hegele RA; Cuchel MA; Barter PJ; Watts GF; Baum SJ; Catapano AL; Chapman MJ; Defesche JC, 2016, 'Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia P', The Lancet Diabetes and Endocrinology, vol. 4, pp. 850 - 861, http://dx.doi.org/10.1016/S2213-8587(16)30041-9

Sultana A; Cochran BJ; Tabet F; Patel M; Torres LC; Barter PJ; Rye KA, 2016, 'Inhibition of inflammatory signaling pathways in 3T3-L1 adipocytes by apolipoprotein A-I', FASEB Journal, vol. 30, pp. 2324 - 2335, http://dx.doi.org/10.1096/fj.201500026R

Siebel AL; Trinh SK; Formosa MF; Mundra PA; Natoli AK; Reddy-Luthmoodoo M; Huynh K; Khan AA; Carey AL; Van Hall G, 2016, 'Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial', Metabolism: Clinical and Experimental, vol. 65, pp. 904 - 914, http://dx.doi.org/10.1016/j.metabol.2016.03.002

Tabet F; Torres LFC; Ong KL; Shrestha S; Choteau SA; Barter PJ; Clifton P; Rye KA, 2016, 'High-density lipoprotein-associated miR-223 is altered after diet-induced weight loss in overweight and obese males', PLoS ONE, vol. 11, http://dx.doi.org/10.1371/journal.pone.0151061

Barter PJ; Rye KA, 2016, 'Coronary artery disease: Scavenger receptor class B1-a target to reduce CHD risk?', Nature Reviews Cardiology, vol. 13, pp. 249 - 250, http://dx.doi.org/10.1038/nrcardio.2016.50

Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2016, 'A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients with Hypertriglyceridemia', American Journal of Cardiology, vol. 117, pp. 1444 - 1448, http://dx.doi.org/10.1016/j.amjcard.2016.02.011

Barter PJ; Rye KA, 2016, 'New era of lipid-lowering drugs', Pharmacological Reviews, vol. 68, pp. 458 - 475, http://dx.doi.org/10.1124/pr.115.012203

Barter PJ; Rye KA, 2016, 'Cholesteryl ester transfer protein inhibition is not yet dead - Pro', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 36, pp. 439 - 441, http://dx.doi.org/10.1161/ATVBAHA.115.306879

Puranik R; Bao S; Bonin AM; Kaur R; Weder JE; Casbolt L; Hambley TW; Lay PA; Barter PJ; Rye KA, 2016, 'A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo', Cell and Bioscience, vol. 6, http://dx.doi.org/10.1186/s13578-016-0076-8

Rosenson RS; Brewer HB; Ansell BJ; Barter P; Chapman MJ; Heinecke JW; Kontush A; Tall AR; Webb NR, 2016, 'Dysfunctional HDL and atherosclerotic cardiovascular disease', Nature Reviews Cardiology, vol. 13, pp. 48 - 60, http://dx.doi.org/10.1038/nrcardio.2015.124

Nicholls SJ; Puri R; Wolski K; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJP; Hu B; Uno K; Kataoka Y, 2016, 'Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial', American Journal of Cardiovascular Drugs, vol. 16, pp. 55 - 65, http://dx.doi.org/10.1007/s40256-015-0146-z

Price TJ; Bruhn MA; Lee CK; Hardingham JE; Townsend AR; Mann KP; Simes J; Weickhardt A; Wrin JW; Wilson K, 2015, 'Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C i', British Journal of Cancer, vol. 112, pp. 963 - 970, http://dx.doi.org/10.1038/bjc.2015.37

Weickhardt AJ; Williams DS; Lee CK; Chionh F; Simes J; Murone C; Wilson K; Parry MM; Asadi K; Scott AM, 2015, 'Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer', British Journal of Cancer, vol. 113, pp. 37 - 45, http://dx.doi.org/10.1038/bjc.2015.209

Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F, 2015, 'TOPGEAR: A randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergro', BMC Cancer, vol. 15, http://dx.doi.org/10.1186/s12885-015-1529-x

Ghersi D; Willson ML; Chan MMK; Simes J; Donoghue E; Wilcken N, 2015, 'Taxane-containing regimens for metastatic breast cancer', Cochrane Database of Systematic Reviews, vol. 2015, http://dx.doi.org/10.1002/14651858.CD003366.pub3

Wain LV; Shrine N; Miller S; Jackson VE; Ntalla I; Artigas MS; Billington CK; Kheirallah AK; Allen R; Cook JP, 2015, 'Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): A genetic association study in UK Biobank', The Lancet Respiratory Medicine, vol. 3, pp. 769 - 781, http://dx.doi.org/10.1016/S2213-2600(15)00283-0

Stevenson ARL; Solomon MJ; Lumley JW; Hewett P; Clouston AD; Gebski VJ; Davies L; Wilson K; Hague W; Simes J, 2015, 'Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: The ALaCaRT randomized clinical trial', JAMA - Journal of the American Medical Association, vol. 314, pp. 1356 - 1363, http://dx.doi.org/10.1001/jama.2015.12009

Tonkin AM; Blankenberg S; Kirby A; Zeller T; Colquhoun DM; Funke-Kaiser A; Hague W; Hunt D; Keech AC; Nestel P, 2015, 'Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study', International Journal of Cardiology, vol. 201, pp. 499 - 507, http://dx.doi.org/10.1016/j.ijcard.2015.07.080

Whittle JR; Lickliter JD; Gan HK; Scott AM; Simes J; Solomon BJ; MacDiarmid JA; Brahmbhatt H; Rosenthal MA, 2015, 'First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma', Journal of Clinical Neuroscience, vol. 22, pp. 1889 - 1894, http://dx.doi.org/10.1016/j.jocn.2015.06.005

Sullivan DR; Watts GF; Nicholls SJ; Barter P; Grenfell R; Chow CK; Tonkin A; Keech A, 2015, 'Clinical Guidelines on Hyperlipidaemia: Recent Developments, Future Challenges and the Need for an Australian Review', Heart Lung and Circulation, vol. 24, pp. 495 - 502, http://dx.doi.org/10.1016/j.hlc.2014.12.009

Barter PJ; Tabet F; Rye KA, 2015, 'Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?', Journal of lipid research, vol. 56, pp. 2045 - 2047, http://dx.doi.org/10.1194/jlr.C063768

Fulcher J; O'Connell R; Voysey M; Emberson J; Blackwell L; Mihaylova B; Simes J; Collins R; Kirby A; Colhoun H, 2015, 'Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials', The Lancet, vol. 385, pp. 1397 - 1405, http://dx.doi.org/10.1016/S0140-6736(14)61368-4

Priglinger M; Arima H; Anderson C; Krause M; Chalmers J; Anderson CS; Huang Y; Wang JG; Arima H; Bath P, 2015, 'No relationship of lipid-lowering agents to hematoma growth: Pooled analysis of the intensive blood pressure reduction in acute cerebral hemorrhage trials studies', Stroke, vol. 46, pp. 857 - 859, http://dx.doi.org/10.1161/STROKEAHA.114.007664

Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2015, 'Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis', European Journal of Preventive Cardiology, vol. 23, pp. 744 - 747, http://dx.doi.org/10.1177/2047487315598710

Barter PJ; Rye KA, 2015, 'Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?', Clinical Therapeutics, vol. 37, pp. 2716 - 2731, http://dx.doi.org/10.1016/j.clinthera.2015.07.021

Nicholls SJ; Lincoff AM; Barter PJ; Brewer HB; Fox KAA; Gibson CM; Grainger C; Menon V; Montalescot G; Rader D, 2015, 'Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial', American Heart Journal, vol. 170, pp. 1061 - 1069, http://dx.doi.org/10.1016/j.ahj.2015.09.007

Rye KA; Barter PJ; Cochran BJ, 2015, 'Apolipoprotein A-I interactions with insulin secretion and production', Current Opinion in Lipidology, http://dx.doi.org/10.1097/MOL.0000000000000253

Rye KA; Barter PJ; Brown AJ, 2015, 'Speed kills in more ways than one: Methamphetamine and atherosclerosis', Atherosclerosis, vol. 243, pp. 654 - 655, http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.034

Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CSB; Barnes EH; Sawkins K; Livingstone A, 2015, 'Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma', Neuro-Oncology, vol. 17, pp. 1504 - 1513, http://dx.doi.org/10.1093/neuonc/nov104

Bisoendial R; Tabet F; Tak PP; Petrides F; Cuesta Torres LF; Hou L; Cook A; Barter P; Weninger W; Rye KA, 2015, 'Apolipoprotein A-I Limits the Negative Effect of Tumor Necrosis Factor on Lymphangiogenesis', Arteriosclerosis, Thrombosis, and Vascular Biology, http://dx.doi.org/10.1161/ATVBAHA.115.305777

Chandrasegaram MD; Goldstein D; Simes J; Gebski V; Kench JG; Gill AJ; Samra JS; Merrett ND; Richardson AJ; Barbour AP, 2015, 'Meta-analysis of radical resection rates and margin assessment in pancreatic cancer', British Journal of Surgery, vol. 102, pp. 1459 - 1472, http://dx.doi.org/10.1002/bjs.9892

Chantrill LA; Nagrial AM; Watson C; Johns AL; Martyn-Smith M; Simpson S; Mead S; Jones MD; Samra JS; Gill AJ, 2015, 'Precision medicine for advanced pancreas cancer: The individualized molecular pancreatic cancer therapy (IMPaCT) Trial', Clinical Cancer Research, vol. 21, pp. 2029 - 2037, http://dx.doi.org/10.1158/1078-0432.CCR-15-0426

Wu BJ; Shrestha S; Ong KL; Johns D; Dunn LL; Hou L; Barter PJ; Rye KA, 2015, 'Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis', International Journal of Cardiology, vol. 199, pp. 204 - 212, http://dx.doi.org/10.1016/j.ijcard.2015.07.014

Barter PJ; Nicholls SJ; Kastelein JJP; Rye KA, 2015, 'Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk?: CETP inhibition as a strategy to reduce cardiovascular risk: The pro case', Circulation, vol. 132, pp. 423 - 432, http://dx.doi.org/10.1161/CIRCULATIONAHA.114.014025

Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2015, 'To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Assoc', Atherosclerosis, vol. 241, pp. 450 - 454, http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.029

Ong KL; Ding J; McClelland RL; Cheung BMY; Criqui MH; Barter PJ; Rye KA; Allison MA, 2015, 'Relationship of pericardial fat with lipoprotein distribution: The Multi-Ethnic study of atherosclerosis', Atherosclerosis, vol. 241, pp. 664 - 670, http://dx.doi.org/10.1016/j.atherosclerosis.2015.06.027

Ong K-L; Januszewski AS; O Connell R; Buizen L; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Scott RS; Taskinen M-R, 2015, 'Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study', Diabetologia, http://dx.doi.org/10.1007/s00125-015-3652-2

Hovingh GK; Kastelein JJP; van Deventer SJH; Round P; Ford J; Saleheen D; Rader DJ; Brewer HB; Barter PJ, 2015, 'Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): A randomised, double-blind, placebo-controlled phase 2 trial', The Lancet, http://dx.doi.org/10.1016/S0140-6736(15)60158-1

Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; Sisk CMC; Dansky H; Mitchel Y, 2015, 'Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the efficacy and tolerability of CETP INhibition with AnacEtrapib) trial', Journal of Clinical Lipidology, vol. 9, pp. 65 - 71, http://dx.doi.org/10.1016/j.jacl.2014.10.005

Borel AL; Nazare JA; Smith J; Aschner P; Barter P; Van Gaal L; Eng Tan C; Wittchen HU; Matsuzawa Y; Kadowaki T, 2015, 'Visceral, subcutaneous abdominal adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance', International Journal of Obesity, vol. 39, pp. 495 - 501, http://dx.doi.org/10.1038/ijo.2014.163

Ong KL; Ding J; McClelland RL; Cheung BMY; Criqui MH; Barter PJ; Rye KA; Allison MA, 2015, 'Relationship of pericardial fat with biomarkers of inflammation and hemostasis, and cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis', Atherosclerosis, vol. 239, pp. 386 - 392, http://dx.doi.org/10.1016/j.atherosclerosis.2015.01.033

Wu BJ; Shrestha S; Ong KL; Johns D; Hou L; Barter PJ; Rye KA, 2015, 'Cholesteryl Ester Transfer Protein Inhibition Enhances Endothelial Repair and Improves Endothelial Function in the Rabbit', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, pp. 628 - 636, http://dx.doi.org/10.1161/ATVBAHA.114.304747

Nazare JA; Smith J; Borel AL; Aschner P; Barter P; Van Gaal L; Tan CE; Wittchen HU; Matsuzawa Y; Kadowaki T, 2015, 'Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA Study)', American Journal of Cardiology, vol. 115, pp. 307 - 315, http://dx.doi.org/10.1016/j.amjcard.2014.10.039

Barter P, 2014, 'International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia', Clinica e Investigacion en Arteriosclerosis, vol. 26, pp. 21 - 22, http://dx.doi.org/10.1016/j.arteri.2013.09.004

Grundy SM; Arai H; Barter P; Bersot TP; Betteridge DJ; Carmena R; Cuevas A; Davidson MH; Genest J; Kesäniemi YA, 2014, 'An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia - Full report', Journal of Clinical Lipidology, vol. 8, pp. 29 - 60, http://dx.doi.org/10.1016/j.jacl.2013.12.005

Puri R; Libby P; Nissen SE; Wolski K; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K, 2014, 'Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: Insights from SATURN', European Heart Journal Cardiovascular Imaging, vol. 15, pp. 380 - 388, http://dx.doi.org/10.1093/ehjci/jet251

Arsenault BJ; Boekholdt SM; Mora S; Demicco DA; Bao W; Tardif JC; Amarenco P; Pedersen T; Barter P; Waters DD, 2014, 'Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL)', American Journal of Cardiology, vol. 113, pp. 1378 - 1382, http://dx.doi.org/10.1016/j.amjcard.2014.01.414

Olsen DA; Hayes JW; Booker DJ; Barter PJ, 2014, 'A Model incorporating disturbance and recovery processes in benthic invertebrate habitat-flow time series', River Research and Applications, vol. 30, pp. 413 - 426, http://dx.doi.org/10.1002/rra.2649

Barter P, 2014, 'Lipoprotein metabolism and CKD: Overview', Clinical and Experimental Nephrology, vol. 18, pp. 243 - 246, http://dx.doi.org/10.1007/s10157-013-0866-9

Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK, 2014, 'Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0114519

Tardif JC; Ballantyne CM; Barter P; Dasseux JL; Fayad ZA; Guertin MC; Kastelein JJP; Keyserling C; Klepp H; Koenig W, 2014, 'Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: A randomized trial', European Heart Journal, vol. 35, pp. 3277 - 3286, http://dx.doi.org/10.1093/eurheartj/ehu171

Mcgrath P; Ghersi D; Simes J; Wilcken N, 2014, 'Larger versus smaller dose of the same drug/s regimen for metastatic breast cancer', Cochrane Database of Systematic Reviews, vol. 2014, http://dx.doi.org/10.1002/14651858.CD003365.pub3

Simes J; Becattini C; Agnelli G; Eikelboom JW; Kirby AC; Mister R; Prandoni P; Brighton TA, 2014, 'Aspirin for the prevention of recurrent venous thromboembolism the INSPIRE collaboration', Circulation, vol. 130, pp. 1062 - 1071, http://dx.doi.org/10.1161/CIRCULATIONAHA.114.008828

Gotto AM; Kher U; Chatterjee MS; Liu Y; Li XS; Vaidya S; Cannon CP; Brinton EA; Moon JE; Shah S, 2014, 'Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with Anacetrapib in the DEFINE study', Journal of Cardiovascular Pharmacology and Therapeutics, vol. 19, pp. 543 - 549, http://dx.doi.org/10.1177/1074248414529621

Karlson BW; Toth PP; Palmer MK; Barter PJ; Nicholls SJ, 2014, 'Achievement of combined goals of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol with three different statins: Results from VOYAGER', IJC Metabolic and Endocrine, vol. 5, pp. 61 - 66, http://dx.doi.org/10.1016/j.ijcme.2014.11.002

Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K, 2014, 'Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: Insights from study of coronary atheroma by intravascular ultrasound: Effect of rosuvastatin', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, pp. 2465 - 2472, http://dx.doi.org/10.1161/ATVBAHA.114.303932

Ong K-L; Januszewski AS; O Connell R; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Hung W-T; Scott RS; Taskinen M-R, 2014, 'The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study', Diabetologia, http://dx.doi.org/10.1007/s00125-014-3458-7

Cochran BJ; Bisoendial RJ; Hou L; Glaros EN; Rossy J; Thomas SR; Barter PJ; Rye KA, 2014, 'Apolipoprotein A-I increases insulin secretion and production from pancreatic β-cells via a G-protein-cAMPPKA-FoxO1-dependent mechanism', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, pp. 2261 - 2267, http://dx.doi.org/10.1161/ATVBAHA.114.304131

Stegman B; Puri R; Cho L; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS, 2014, 'High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: Insights from SATURN', Diabetes Care, vol. 37, pp. 3114 - 3120, http://dx.doi.org/10.2337/dc14-1121

Lim S; Barter P, 2014, 'Antioxidant effects of statins in the management of cardiometabolic disorders', Journal of Atherosclerosis and Thrombosis, vol. 21, pp. 997 - 1010, http://dx.doi.org/10.5551/jat.24398

Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K, 2014, 'Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: Insights from saturn', JACC: Cardiovascular Imaging, vol. 7, pp. 1013 - 1022, http://dx.doi.org/10.1016/j.jcmg.2014.04.019

Ong KL; McClelland RL; Rye KA; Cheung BMY; Post WS; Vaidya D; Criqui MH; Cushman M; Barter PJ; Allison MA, 2014, 'The relationship between insulin resistance and vascular calcification in coronary arteries, and the thoracic and abdominal aorta: The multi-ethnic study of atherosclerosis', Atherosclerosis, vol. 236, pp. 257 - 262, http://dx.doi.org/10.1016/j.atherosclerosis.2014.07.015

Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR, 2014, 'Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor d', Journal of the American College of Cardiology, vol. 63, pp. 2365 - 2373, http://dx.doi.org/10.1016/j.jacc.2014.02.538

Ong KL; Allison MA; Cheung BMY; Wu BJ; Barter PJ; Rye KA, 2014, 'The relationship between total Bilirubin levels and total mortality in older adults: The United States national health and nutrition examination survey (NHANES) 1999-2004', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0094479

Ong KL; Barter PJ; Waters DD, 2014, 'Cardiovascular drugs that increase the risk of new-onset diabetes', American Heart Journal, vol. 167, pp. 421 - 428, http://dx.doi.org/10.1016/j.ahj.2013.12.025

Tabet F; Vickers KC; Cuesta Torres LF; Wiese CB; Shoucri BM; Lambert G; Catherinet C; Prado-Lourenco L; Levin MG; Thacker S, 2014, 'HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells', Nature Communications, vol. 5, http://dx.doi.org/10.1038/ncomms4292

Ong K-L; Rye K-A; Barter PJ; Waters DD; Messig M; DeMicco DA, 2014, 'Effect of Change in Body Weight on Incident Diabetes Mellitus in Patients With Stable Coronary Artery Disease Treated With Atorvastatin (from the Treating to New Targets Study)', American Journal of Cardiology, http://dx.doi.org/10.1016/j.amjcard.2014.02.011

McGrath KC; Li XH; Whitworth PT; Kasz R; Tan JT; McLennan SV; Celermajer DS; Barter PJ; Rye KA; Heather AK, 2014, 'High density lipoproteins improve insulin sensitivity in high-fat diet-fed mice by suppressing hepatic inflammation', Journal of Lipid Research, vol. 55, pp. 421 - 430, http://dx.doi.org/10.1194/jlr.M043281

Wu BJ; Ong KL; Shrestha S; Chen K; Tabet F; Barter PJ; Rye KA, 2014, 'Inhibition of arthritis in the lewis rat by apolipoprotein A-I and reconstituted high-density lipoproteins', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, pp. 543 - 551, http://dx.doi.org/10.1161/ATVBAHA.113.302832

Rye KA; Barter PJ, 2014, 'Thematic review series: High density lipoprotein structure, function, and metabolism cardioprotective functions of HDLs 1', Journal of Lipid Research, vol. 55, pp. 168 - 179, http://dx.doi.org/10.1194/jlr.R039297

Fruchart JC; Davignon J; Hermans MP; Al-Rubeaan K; Amarenco P; Assmann G; Barter P; Betteridge J; Bruckert E; Cuevas A, 2014, 'Residual macrovascular risk in 2013: What have we learned?', Cardiovascular Diabetology, vol. 13, http://dx.doi.org/10.1186/1475-2840-13-26

Grundy SM; Arai H; Barter P; Bersot TP; Betteridge DJ; Carmena R; Cuevas A; Davidson MH; Genest J; Kesäniemi YA, 2014, 'An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. Executive summary.', Atherosclerosis, vol. 232, pp. 410 - 413, http://dx.doi.org/10.1016/j.atherosclerosis.2013.11.031

Rye KA; Barter PJ, 2014, 'Regulation of high-density lipoprotein metabolism', Circulation Research, vol. 114, pp. 143 - 156, http://dx.doi.org/10.1161/CIRCRESAHA.114.300632

Gotto AM; Cannon CP; Li XS; Vaidya S; Kher U; Brinton EA; Davidson M; Moon JE; Shah S; Dansky HM, 2014, 'Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for', American Journal of Cardiology, vol. 113, pp. 76 - 83, http://dx.doi.org/10.1016/j.amjcard.2013.08.041

Schwartz GG; Olsson AG; Barter PJ, 2013, 'Dalcetrapib in patients with an acute coronary syndrome.', The New England journal of medicine, vol. 368, pp. 869 - 870, http://dx.doi.org/10.1056/NEJMc1300057

Barter PJ, 2013, 'High density lipoprotein: a therapeutic target in type 2 diabetes.', Endocrinol Metab (Seoul), vol. 28, pp. 169 - 177, http://dx.doi.org/10.3803/EnM.2013.28.3.169

Davidson M; Liu SX; Barter P; Brinton EA; Cannon CP; Gotto AM; Leary ET; Shah S; Stepanavage M; Mitchel Y, 2013, 'Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib', Journal of Lipid Research, vol. 54, pp. 467 - 472, http://dx.doi.org/10.1194/jlr.M032615

Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK, 2013, 'Erratum: Prediction of cardiovascular events in statin-treated patients by lipid and non-lipid biomarkers (Journal of the American College of Cardiology (2011) 57 (63-69))', Journal of the American College of Cardiology, vol. 61, pp. 1750, http://dx.doi.org/10.1016/j.jacc.2013.03.006

Karlson BW; Nicholls SJ; Lundman P; Palmer MK; Barter PJ, 2013, 'Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥50% reduction in high-risk patients: Results from VOYAGER', Atherosclerosis, vol. 228, pp. 265 - 269, http://dx.doi.org/10.1016/j.atherosclerosis.2013.02.027

Smith J; Nazare JA; Borel AL; Aschner P; Barter PJ; Van Gaal L; Matsuzawa Y; Kadowaki T; Ross R; Brulle-Wohlhueter C, 2013, 'Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: Re', Diabetes, Obesity and Metabolism, vol. 15, pp. 629 - 641, http://dx.doi.org/10.1111/dom.12075

Puri R; Nissen SE; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; St. John J; Wolski K, 2013, 'Factors underlying regression of coronary atheroma with potent statin therapy', European Heart Journal, vol. 34, http://dx.doi.org/10.1093/eurheartj/eht084

Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J, 2013, 'Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carci', Journal of Clinical Oncology, vol. 31, pp. 2477 - 2484, http://dx.doi.org/10.1200/JCO.2012.46.0543

Toth PP; Barter PJ; Rosenson RS; Boden WE; Chapman MJ; Cuchel M; D'Agostino RB; Davidson MH; Davidson WS; Heinecke JW, 2013, 'High-density lipoproteins: A consensus statement from the National Lipid Association', Journal of Clinical Lipidology, vol. 7, pp. 484 - 525, http://dx.doi.org/10.1016/j.jacl.2013.08.001

Thorgeirsson TE; Gudbjartsson DF; Sulem P; Besenbacher S; Styrkarsdottir U; Thorleifsson G; Walters GB; Furberg H; Sullivan PF; Marchini J, 2013, 'A common biological basis of obesity and nicotine addiction', Translational Psychiatry, vol. 3, pp. 1 - 7, http://dx.doi.org/10.1038/tp.2013.81

Palmer MK; Nicholls SJ; Lundman P; Barter PJ; Karlson BW, 2013, 'Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: An analysis from the VOYAGER database', European Journal of Preventive Cardiology, vol. 20, pp. 1080 - 1087, http://dx.doi.org/10.1177/2047487313489875

Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K, 2013, 'Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy', European Heart Journal, vol. 34, pp. 3182 - 3190, http://dx.doi.org/10.1093/eurheartj/eht260

White HD; Simes J; Stewart RAH; Blankenberg S; Barnes EH; Marschner IC; Thompson P; West M; Zeller T; Colquhoun DM, 2013, 'Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: Results from the long-term intervention with pravastatin', Journal of the American Heart Association, vol. 2, pp. 1 - 13, http://dx.doi.org/10.1161/JAHA.113.000360

Huijgen R; Boekholdt SM; Arsenault BJ; Bao W; Davaine JM; Tabet F; Petrides F; Rye KA; DeMicco DA; Barter PJ, 2013, 'Erratum: Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) Trial (Journal of the American College of Cardiology (2012) 59 (1778-1784))', Journal of the American College of Cardiology, vol. 61, pp. 1751, http://dx.doi.org/10.1016/j.jacc.2013.04.002

Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K, 2013, 'C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy', Circulation, vol. 128, pp. 2395 - 2403, http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004243

Ong KL; Wu BJ; Cheung BMY; Barter PJ; Rye KA, 2013, 'Arthritis: Its prevalence, Risk factors, And association with cardiovascular diseases in the United States, 1999 to 2008', Annals of Epidemiology, vol. 23, pp. 80 - 86, http://dx.doi.org/10.1016/j.annepidem.2012.11.008

Ong KL; Allison MA; Cheung BMY; Wu BJ; Barter PJ; Rye KA, 2013, 'Trends in C-reactive protein levels in US adults from 1999 to 2010', American Journal of Epidemiology, vol. 177, pp. 1430 - 1442, http://dx.doi.org/10.1093/aje/kws443

Rosenson RS; Brewer HB; Ansell B; Barter P; Chapman MJ; Heinecke JW; Kontush A; Tall AR; Webb NR, 2013, 'Translation of high-density lipoprotein function into clinical practice: Current prospects and future challenges', Circulation, vol. 128, pp. 1256 - 1267, http://dx.doi.org/10.1161/CIRCULATIONAHA.113.000962

Chapman MJ; Giral P; Barter PJ, 2013, 'The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: Insight from EPIC-Norfolk and JUPITER', European Heart Journal, vol. 34, pp. 1318 - 1320, http://dx.doi.org/10.1093/eurheartj/eht074

Wu BJ; Chen K; Shrestha S; Ong KL; Barter PJ; Rye KA, 2013, 'High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3β-hydroxysteroid-[INCREMENT]24 reductase expression and inducing heme oxygenase-1', Circulation Research, vol. 112, pp. 278 - 288, http://dx.doi.org/10.1161/CIRCRESAHA.111.300104

Arsenault BJ; Boekholdt SM; Hovingh GK; Hyde CL; DeMicco DA; Chatterjee A; Barter P; Deedwania P; Waters DD; LaRosa JC, 2012, 'The 719Arg variant of kIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-loweri', Circulation: Cardiovascular Genetics, vol. 5, pp. 51 - 57, http://dx.doi.org/10.1161/CIRCGENETICS.111.960252

Nicholls SJ; Gordon A; Johannson J; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJP; Wong NC; Borgman MRN; Nissen SE, 2012, 'ApoA-I induction as a potential cardioprotective strategy: Rationale for the SUSTAIN and ASSURE studies', Cardiovascular Drugs and Therapy, vol. 26, pp. 181 - 187, http://dx.doi.org/10.1007/s10557-012-6373-5

Karlson BW; Barter PJ; Palmer MK; Lundman P; Nicholls SJ, 2012, 'Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: Results from VOYAGER', Nutrition, Metabolism and Cardiovascular Diseases, vol. 22, pp. 697 - 703, http://dx.doi.org/10.1016/j.numecd.2012.03.003

Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA, 2012, 'Effects of dalcetrapib in patients with a recent acute coronary syndrome', New England Journal of Medicine, vol. 367, pp. 2089 - 2099, http://dx.doi.org/10.1056/NEJMoa1206797

Morales-Villegas E; Moreno-Virgen G; Barter PJ, 2012, 'CETP pharmacological manipulation transforming human into mouse: Is this still a viable hypothesis?', Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, vol. 12, pp. 266 - 278, http://dx.doi.org/10.2174/187152212803521057

Wu BJ; Chen K; Barter PJ; Rye KA, 2012, 'Niacin inhibits vascular inflammation via the induction of heme oxygenase-1', Circulation, vol. 125, pp. 150 - 158, http://dx.doi.org/10.1161/CIRCULATIONAHA.111.053108

Rye KA; Barter PJ, 2012, 'Predictive value of different HDL particles for the protection against or risk of coronary heart disease', Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, vol. 1821, pp. 473 - 480, http://dx.doi.org/10.1016/j.bbalip.2011.10.012

Drew BG; Rye KA; Duffy SJ; Barter P; Kingwell BA, 2012, 'The emerging role of HDL in glucose metabolism', Nature Reviews Endocrinology, vol. 8, pp. 237 - 245, http://dx.doi.org/10.1038/nrendo.2011.235

Rye KA; Barter PJ, 2012, 'The inhibition of cholesteryl ester transfer protein: A long and winding road', Journal of Lipid Research, vol. 53, pp. 1039 - 1041, http://dx.doi.org/10.1194/jlr.E027334

Barter PJ; Rye KA, 2012, 'Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk', Journal of Lipid Research, vol. 53, pp. 1755 - 1766, http://dx.doi.org/10.1194/jlr.R024075

Barter PJ; Rye KA; Beltangady MS; Ports WC; Duggan WT; Boekholdt SM; DeMicco DA; Kastelein JJP; Shear CL, 2012, 'Relationship between atorvastatin dose and the harm caused by torcetrapib', Journal of Lipid Research, vol. 53, pp. 2436 - 2442, http://dx.doi.org/10.1194/jlr.P026328

Tso C; Rye KA; Barter P, 2012, 'Phenotypic and functional changes in blood monocytes following adherence to endothelium', PLoS ONE, vol. 7, http://dx.doi.org/10.1371/journal.pone.0037091

Huijgen R; Boekholdt SM; Arsenault BJ; Bao W; Davaine JM; Tabet F; Petrides F; Rye KA; Demicco DA; Barter PJ, 2012, 'Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: A nested case-control study', Journal of the American College of Cardiology, vol. 59, pp. 1778 - 1784, http://dx.doi.org/10.1016/j.jacc.2011.12.043

Mihaylova B; Emberson J; Blackwell L; Keech A; Simes J; Barnes EH; Voysey M; Gray A; Collins R; Baigent C, 2012, 'The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials', The Lancet, vol. 380, pp. 581 - 590, http://dx.doi.org/10.1016/S0140-6736(12)60367-5

Emberson JR; Kearney PM; Blackwell L; Newman C; Reith C; Bhala N; Holland L; Peto R; Keech A; Collins R, 2012, 'Lack of effect of lowering LDL cholesterol on cancer: Meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy', PLoS ONE, vol. 7, http://dx.doi.org/10.1371/journal.pone.0029849

Dastani Z; Hivert MF; Timpson N; Perry JRB; Yuan X; Scott RA; Henneman P; Heid IM; Kizer JR; Lyytikäinen LP, 2012, 'Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: A multi-ethnic meta-analysis of 45,891 individuals', PLoS Genetics, vol. 8, http://dx.doi.org/10.1371/journal.pgen.1002607

Ong KL; Rye KA; O'Connell R; Jenkins AJ; Brown C; Xu A; Sullivan DR; Barter PJ; Keech AC, 2012, 'Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes', Journal of Clinical Endocrinology and Metabolism, vol. 97, pp. 4701 - 4708, http://dx.doi.org/10.1210/jc.2012-2267

Dear RF; Barratt AL; Evans A; Simes J; Newsom J; Kent D; Crossing S; Holliday C; Segelov E; Hruby G, 2012, 'Identifying and prioritising gaps in colorectal cancer trials research in Australia', Medical Journal of Australia, vol. 197, pp. 507 - 511, http://dx.doi.org/10.5694/mja12.10623

Waters DD; Ho JE; DeMicco DA; Breazna A; Arsenault BJ; Wun CC; Kastelein JJ; Colhoun H; Barter P, 2011, 'Predictors of new-onset diabetes in patients treated with atorvastatin: Results from 3 large randomized clinical trials', Journal of the American College of Cardiology, vol. 57, pp. 1535 - 1545, http://dx.doi.org/10.1016/j.jacc.2010.10.047

Preiss D; Seshasai SRK; Welsh P; Murphy SA; Ho JE; Waters DD; DeMicco DA; Barter P; Cannon CP; Sabatine MS, 2011, 'Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis', JAMA - Journal of the American Medical Association, vol. 305, pp. 2556 - 2564, http://dx.doi.org/10.1001/jama.2011.860

Nicholls SJ; Borgman M; Nissen SE; Raichlen JS; Ballantyne C; Barter P; Chapman MJ; Erbel R; Libby P, 2011, 'Impact of statins on progression of atherosclerosis: Rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN)', Current Medical Research and Opinion, vol. 27, pp. 1119 - 1129, http://dx.doi.org/10.1185/03007995.2011.570746

Arsenault BJ; Barter P; Demicco DA; Bao W; Preston GM; Larosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK, 2011, 'Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers', Journal of the American College of Cardiology, vol. 57, pp. 63 - 69, http://dx.doi.org/10.1016/j.jacc.2010.06.052

Chan JCN; Chan SP; Deerochanawong C; Go RT; Lee KO; Ma RCW; Pan CY; Sheu WHH; Barter P, 2011, 'Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: What we know and don't know', Diabetes Research and Clinical Practice, vol. 94, pp. 1 - 13, http://dx.doi.org/10.1016/j.diabres.2011.05.034

Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K, 2011, 'Effect of two intensive statin regimens on progression of coronary disease', New England Journal of Medicine, vol. 365, pp. 2078 - 2087, http://dx.doi.org/10.1056/NEJMoa1110874

Barter P, 2011, 'HDL-C: Role as a risk modifier', Atherosclerosis Supplements, vol. 12, pp. 267 - 270, http://dx.doi.org/10.1016/S1567-5688(11)70885-6

Barter PJ, 2011, 'The causes and consequences of low levels of high density lipoproteins in patients with diabetes', Diabetes and Metabolism Journal, vol. 35, pp. 101 - 106, http://dx.doi.org/10.4093/dmj.2011.35.2.101

Watts GF; Sullivan DR; Poplawski N; van Bockxmeer F; Hamilton-Craig I; Clifton PM; O'Brien R; Bishop W; George P; Barter PJ, 2011, 'Familial hypercholesterolaemia: A model of care for Australasia', Atherosclerosis Supplements, vol. 12, pp. 221 - 263, http://dx.doi.org/10.1016/j.atherosclerosissup.2011.06.001

Barter P, 2011, 'Raising HDL-C can be achieved by both lifestyle changes and pharmacological means. Introduction.', Atherosclerosis. Supplements, vol. 12, pp. 265 - 266

Speliotes EK; Yerges-Armstrong LM; Wu J; Hernaez R; Kim LJ; Palmer CD; Gudnason V; Eiriksdottir G; Garcia ME; Launer LJ, 2011, 'Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits', PLoS Genetics, vol. 7, http://dx.doi.org/10.1371/journal.pgen.1001324

Reimers GJ; Jackson CL; Rickards J; Chan PY; Cohn JS; Rye KA; Barter PJ; Rodgers KJ, 2011, 'Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I', Cardiovascular Research, vol. 91, pp. 37 - 44, http://dx.doi.org/10.1093/cvr/cvr057

Di Bartolo BA; Nicholls SJ; Bao S; Rye KA; Heather AK; Barter PJ; Bursill C, 2011, 'The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins', Atherosclerosis, vol. 217, pp. 395 - 400, http://dx.doi.org/10.1016/j.atherosclerosis.2011.04.001

Barter P; Rye KA, 2011, 'Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?', Trends in Pharmacological Sciences, vol. 32, pp. 694 - 699, http://dx.doi.org/10.1016/j.tips.2011.07.004

Di Bartolo BA; Vanags LZ; Tan JT; Bao S; Rye KA; Barter PJ; Bursill CA, 2011, 'The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit.', Lipids in health and disease, vol. 10, pp. 224, http://dx.doi.org/10.1186/1476-511X-10-224

Barter PJ; Rye KA; Tardif JC; Waters DD; Matthijs BS; Breazna A; Kastelein JJP, 2011, 'Effect of torcetrapib on glucose, insulin, and hemoglobin a1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (Illuminate) Trial', Circulation, vol. 124, pp. 555 - 562, http://dx.doi.org/10.1161/CIRCULATIONAHA.111.018259

Tabet F; Lambert G; Cuesta Torres LF; Hou L; Sotirchos I; Touyz RM; Jenkins AJ; Barter PJ; Rye KA, 2011, 'Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, pp. 1192 - 1200, http://dx.doi.org/10.1161/ATVBAHA.110.222000

Ong KL; Barter PJ; Rye KA, 2011, 'Response to statin use and serum bilirubin levels', Atherosclerosis, vol. 219, pp. 392, http://dx.doi.org/10.1016/j.atherosclerosis.2011.09.007

Ong KL; Wu BJ; Cheung BMY; Barter PJ; Rye KA, 2011, 'Association of lower total bilirubin level with statin usage: The United States National Health and Nutrition Examination Survey 1999-2008', Atherosclerosis, vol. 219, pp. 728 - 733, http://dx.doi.org/10.1016/j.atherosclerosis.2011.07.094

Barter PJ; Brandrup-Wognsen G; Palmer MK; Nicholls SJ, 2010, 'Effect of statins on HDL-C: A complex process unrelated to changes in LDL-C: Analysis of the VOYAGER database', Journal of Lipid Research, vol. 51, pp. 1546 - 1553, http://dx.doi.org/10.1194/jlr.P002816

Waterworth DM; Ricketts SL; Song K; Chen L; Zhao JH; Ripatti S; Aulchenko YS; Zhang W; Yuan X; Lim N, 2010, 'Genetic variants influencing circulating lipid levels and risk of coronary artery disease', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 2264 - 2276, http://dx.doi.org/10.1161/ATVBAHA.109.201020

Dupuis J; Langenberg C; Prokopenko I; Saxena R; Soranzo N; Jackson AU; Wheeler E; Glazer NL; Bouatia-Naji N; Gloyn AL, 2010, 'New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk', Nature Genetics, vol. 42, pp. 105 - 116, http://dx.doi.org/10.1038/ng.520

Dupuis J; Langenberg C; Prokopenko I; Saxena R; Soranzo N; Jackson AU; Wheeler E; Glazer NL; Bouatia-Naji N; Gloyn AL, 2010, 'Erratum: New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk (Nature Genetics (2010) 42 (105-116))', Nature Genetics, vol. 42, pp. 464, http://dx.doi.org/10.1038/ng0510-464a

Taskinen MR; Barter PJ; Ehnholm C; Sullivan DR; Mann K; Simes J; Best JD; Hamwood S; Keech AC, 2010, 'Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes', Diabetologia, vol. 53, pp. 1846 - 1855, http://dx.doi.org/10.1007/s00125-010-1806-9

Barter PJ, 2010, 'Point: The relationship between cholesteryl ester transfer protein and cardiovascular risk', Clinical Chemistry, vol. 56, pp. 1547 - 1549, http://dx.doi.org/10.1373/clinchem.2010.150565

Cannon CP; Shah S; Dansky HM; Davidson M; Brinton EA; Gotto AM; Stepanavage M; Liu SX; Gibbons P; Ashraf TB, 2010, 'Safety of anacetrapib in patients with or at high risk for coronary heart disease', New England Journal of Medicine, vol. 363, pp. 2406 - 2415, http://dx.doi.org/10.1056/NEJMoa1009744

Laurila PP; Naukkarinen J; Kristiansson K; Ripatti S; Kauttu T; Silander K; Salomaa V; Perola M; Karhunen PJ; Barter PJ, 2010, 'Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 346 - 352, http://dx.doi.org/10.1161/ATVBAHA.109.188912

Liu JZ; Tozzi F; Waterworth DM; Pillai SG; Muglia P; Middleton L; Berrettini W; Knouff CW; Yuan X; Waeber G, 2010, 'Meta-analysis and imputation refines the association of 15q25 with smoking quantity', Nature Genetics, vol. 42, pp. 436 - 440, http://dx.doi.org/10.1038/ng.572

Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ, 2010, 'Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER)', American Journal of Cardiology, vol. 105, pp. 69 - 76, http://dx.doi.org/10.1016/j.amjcard.2009.08.651

Baigent C; Blackwell L; Emberson J; Holland LE; Reith C; Bhala N; Peto R; Barnes EH; Keech A; Simes J, 2010, 'Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials', The Lancet, vol. 376, pp. 1670 - 1681, http://dx.doi.org/10.1016/S0140-6736(10)61350-5

Tebbutt NC; Wilson K; Gebski VJ; Cummins MM; Zannino D; Van Hazel GA; Robinson B; Broad A; Ganju V; Ackland SP, 2010, 'Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study', Journal of Clinical Oncology, vol. 28, pp. 3191 - 3198, http://dx.doi.org/10.1200/JCO.2009.27.7723

Bursill CA; Castro ML; Beattie DT; Nakhla S; Van Der Vorst E; Heather AK; Barter PJ; Rye KA, 2010, 'High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 1773 - 1778, http://dx.doi.org/10.1161/ATVBAHA.110.211342

Wu BJ; Yan L; Charlton F; Witting P; Barter PJ; Rye KA, 2010, 'Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 968 - 975, http://dx.doi.org/10.1161/ATVBAHA.109.201129

Nobécourt E; Tabet F; Lambert G; Puranik R; Bao S; Yan L; Davies MJ; Brown BE; Jenkins AJ; Dusting GJ, 2010, 'Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 766 - 772, http://dx.doi.org/10.1161/ATVBAHA.109.201715

Tabet F; Remaley AT; Segaliny AI; Millet J; Yan L; Nakhla S; Barter PJ; Rye KA; Lambert G, 2010, 'The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 246 - 252, http://dx.doi.org/10.1161/ATVBAHA.109.200196

Fryirs MA; Barter PJ; Appavoo M; Tuch BE; Tabet F; Heather AK; Rye KA, 2010, 'Effects of high-density lipoproteins on pancreatic β-cell insulin secretion', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 1642 - 1648, http://dx.doi.org/10.1161/ATVBAHA.110.207373

Patel S; Di Bartolo BA; Nakhla S; Heather AK; Mitchell TW; Jessup W; Celermajer DS; Barter PJ; Rye KA, 2010, 'Anti-inflammatory effects of apolipoprotein A-I in the rabbit', Atherosclerosis, vol. 212, pp. 392 - 397, http://dx.doi.org/10.1016/j.atherosclerosis.2010.05.035

Taskinen MR; Sullivan DR; Ehnholm C; Whiting M; Zannino D; Simes RJ; Keech AC; Barter PJ, 2009, 'Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, pp. 950 - 955, http://dx.doi.org/10.1161/ATVBAHA.108.178228

Ling H; Waterworth DM; Stirnadel HA; Pollin TI; Barter PJ; Kesäniemi YA; Mahley RW; McPherson R; Waeber G; Bersot TP, 2009, 'Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: The GEMS study', Obesity, vol. 17, pp. 737 - 744, http://dx.doi.org/10.1038/oby.2008.625

Cannon CP; Dansky HM; Davidson M; Gotto AM; Brinton EA; Gould AL; Stepanavage M; Liu SX; Shah S; Rubino J, 2009, 'Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib', American Heart Journal, vol. 158, http://dx.doi.org/10.1016/j.ahj.2009.07.028

Barter P; MacDonald I, 2009, 'Australia's Heart Research Institute: A remarkable institution in the Southern Hemisphere', European Heart Journal, vol. 30, pp. 2548 - 2550, http://dx.doi.org/10.1093/eurheartj/ehp393

Chirovsky DR; Fedirko V; Cui Y; Sazonov V; Barter P, 2009, 'Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: A systematic review', European Journal of Cardiovascular Prevention and Rehabilitation, vol. 16, pp. 404 - 423, http://dx.doi.org/10.1097/HJR.0b013e32832c8891

Brent Richards J; Waterworth D; O'Rahilly S; Hivert MF; Loos RJF; Perry JRB; Tanaka T; Timpson NJ; Semple RK; Soranzo N, 2009, 'A genome-wide association study reveals variants in ARL15 that influence adiponectin levels', PLoS Genetics, vol. 5, http://dx.doi.org/10.1371/journal.pgen.1000768

Barter P, 2009, 'Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial', American Journal of Cardiology, vol. 104, pp. 10E - 15E, http://dx.doi.org/10.1016/j.amjcard.2009.09.014

Grover SA; Kaouache M; Joseph L; Barter P; Davignon J, 2009, 'Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels', Archives of Internal Medicine, vol. 169, pp. 1775 - 1780, http://dx.doi.org/10.1001/archinternmed.2009.328

Schwartz GG; Olsson AG; Ballantyne CM; Barter PJ; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJV; Shah PK, 2009, 'Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome', American Heart Journal, vol. 158, http://dx.doi.org/10.1016/j.ahj.2009.09.017

Patel S; Drew BG; Nakhla S; Duffy SJ; Murphy AJ; Barter PJ; Rye KA; Chin-Dusting J; Hoang A; Sviridov D, 2009, 'Reconstituted High-Density Lipoprotein Increases Plasma High-Density Lipoprotein Anti-Inflammatory Properties and Cholesterol Efflux Capacity in Patients With Type 2 Diabetes', Journal of the American College of Cardiology, vol. 53, pp. 962 - 971, http://dx.doi.org/10.1016/j.jacc.2008.12.008

Peshavariya H; Dusting GJ; Di Bartolo B; Rye KA; Barter PJ; Jiang F, 2009, 'Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts', Free Radical Research, vol. 43, pp. 772 - 782, http://dx.doi.org/10.1080/10715760903045304

Fryirs M; Barter PJ; Rye KA, 2009, 'Cholesterol metabolism and pancreatic β-cell function', Current Opinion in Lipidology, vol. 20, pp. 159 - 164, http://dx.doi.org/10.1097/MOL.0b013e32832ac180

McGrath KCY; Li XH; Puranik R; Liong EC; Tan JTM; Dy VM; Dibartolo BA; Barter PJ; Rye KA; Heather AK, 2009, 'Role of 3β-hydroxysteroid-Δ24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, pp. 877 - 882, http://dx.doi.org/10.1161/ATVBAHA.109.184663

Rye KA; Bursill CA; Lambert G; Tabet F; Barter PJ, 2009, 'The metabolism and anti-atherogenic properties of HDL', Journal of Lipid Research, vol. 50, http://dx.doi.org/10.1194/jlr.R800034-JLR200

Patel S; Puranik R; Nakhla S; Lundman P; Stocker R; Wang XS; Lambert G; Rye KA; Barter PJ; Nicholls SJ, 2009, 'Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins', Atherosclerosis, vol. 204, pp. 424 - 428, http://dx.doi.org/10.1016/j.atherosclerosis.2008.07.047

Barter P; Shear CL; Revkin JH, 2008, 'The authors reply', New England Journal of Medicine, vol. 358, pp. 1863 - 1864

Shah SJ; Waters DD; Barter P; Kastelein JJP; Shepherd J; Wenger NK; DeMicco DA; Breazna A; LaRosa JC, 2008, 'Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery', Journal of the American College of Cardiology, vol. 51, pp. 1938 - 1943, http://dx.doi.org/10.1016/j.jacc.2007.12.054

Barter P; Ginsberg HN, 2008, 'Effectiveness of Combined Statin Plus Omega-3 Fatty Acid Therapy for Mixed Dyslipidemia', American Journal of Cardiology, vol. 102, pp. 1040 - 1045, http://dx.doi.org/10.1016/j.amjcard.2008.05.056

Stirnadel H; Lin X; Ling H; Song K; Barter P; Kesäniemi YA; Mahley R; McPherson R; Waeber G; Bersot T, 2008, 'Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: The GEMS Study', Atherosclerosis, vol. 197, pp. 868 - 876, http://dx.doi.org/10.1016/j.atherosclerosis.2007.07.038

Sandhu MS; Waterworth DM; Debenham SL; Wheeler E; Papadakis K; Zhao JH; Song K; Yuan X; Johnson T; Ashford S, 2008, 'LDL-cholesterol concentrations: a genome-wide association study', The Lancet, vol. 371, pp. 483 - 491, http://dx.doi.org/10.1016/S0140-6736(08)60208-1

Kastelein JJP; Van Der Steeg WA; Holme I; Gaffney M; Cater NB; Barter P; Deedwania P; Olsson AG; Boekholdt SM; Demicco DA, 2008, 'Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment', Circulation, vol. 117, pp. 3002 - 3009, http://dx.doi.org/10.1161/CIRCULATIONAHA.107.713438

Lambert G; Ancellin N; Charlton F; Comas D; Pilot J; Keech A; Patel S; Sullivan DR; Cohn JS; Rye KA, 2008, 'Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment', Clinical Chemistry, vol. 54, pp. 1038 - 1045, http://dx.doi.org/10.1373/clinchem.2007.099747

Rye KA; Barter PJ, 2008, 'Antiinflammatory actions of HDL. A new insight', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, pp. 1890 - 1891, http://dx.doi.org/10.1161/ATVBAHA.108.173575

Settasatian N; Barter PJ; Rye KA, 2008, 'Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein', Journal of Lipid Research, vol. 49, pp. 115 - 126, http://dx.doi.org/10.1194/jlr.M700220-JLR200

Puranik R; Bao S; Nobecourt E; Nicholls SJ; Dusting GJ; Barter PJ; Celermajer DS; Rye KA, 2008, 'Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo', Atherosclerosis, vol. 196, pp. 240 - 247, http://dx.doi.org/10.1016/j.atherosclerosis.2007.05.008

Homer VM; Marais AD; Charlton F; Laurie AD; Hurndell N; Scott R; Mangili F; Sullivan DR; Barter PJ; Rye KA, 2008, 'Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa', Atherosclerosis, vol. 196, pp. 659 - 666, http://dx.doi.org/10.1016/j.atherosclerosis.2007.07.022

Barter PJ; Rye KA, 2008, 'Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, pp. 39 - 46, http://dx.doi.org/10.1161/ATVBAHA.107.148817

Nobécourt E; Zeng J; Davies MJ; Brown BE; Yadav S; Barter PJ; Rye KA, 2008, 'Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I', Diabetologia, vol. 51, pp. 1008 - 1017, http://dx.doi.org/10.1007/s00125-008-0986-z

Nunn AVW; Bell J; Barter P, 2007, 'The integration of lipid-sensing and anti-inflammatory effects: How the PPARs play a role in metabolic balance', Nuclear Receptor, vol. 5, http://dx.doi.org/10.1186/1478-1336-5-1

Barter PJ; Shear CL, 2007, 'Aggressive management of obesity in children and young adults: The known challenges and potential opportunities', Clinical Pharmacology and Therapeutics, vol. 81, pp. 627 - 630, http://dx.doi.org/10.1038/sj.clpt.6100162

Kastelein JJP; Van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL, 2007, 'Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia', New England Journal of Medicine, vol. 356, pp. 1620 - 1630, http://dx.doi.org/10.1056/NEJMoa071359

Balkau B; Deanfield JE; Després JP; Bassand JP; Fox KAA; Smith SC; Barter P; Tan CE; Van Gaal L; Wittchen HU, 2007, 'International day for the evaluation of abdominal obesity (IDEA): A study of waist circumference, cardiovascular disease, and diabetes mellitus in 168 000 primary care patients in 63 countries', Circulation, vol. 116, pp. 1942 - 1951, http://dx.doi.org/10.1161/CIRCULATIONAHA.106.676379

Barter P; Gotto AM; LaRosa JC; Maroni J; Szarek M; Grundy SM; Kastelein JJP; Bittner V; Fruchart JC, 2007, 'HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events', New England Journal of Medicine, vol. 357, pp. 1301 - 1310, http://dx.doi.org/10.1056/NEJMoa064278

Barter PJ; Caulfield M; Eriksson M; Grundy SM; Kastelein JJP; Komajda M; Lopez-Sendon J; Mosca L; Tardif JC; Waters DD, 2007, 'Effects of torcetrapib in patients at high risk for coronary events', New England Journal of Medicine, vol. 357, pp. 2109 - 2122, http://dx.doi.org/10.1056/NEJMoa0706628

Barter P; McPherson YR; Song K; Kesäniemi YA; Mahley R; Waeber G; Bersot T; Mooser V; Waterworth D; Grundy SM, 2007, 'Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia', Journal of Clinical Endocrinology and Metabolism, vol. 92, pp. 2041 - 2045, http://dx.doi.org/10.1210/jc.2006-2219

Nobecourt E; Davies MJ; Brown BE; Curtiss LK; Bonnet DJ; Charlton F; Januszewski AS; Jenkins AJ; Barter PJ; Rye KA, 2007, 'The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase', Diabetologia, vol. 50, pp. 643 - 653, http://dx.doi.org/10.1007/s00125-006-0574-z

Barter PJ; Puranik R; Rye KA, 2007, 'New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease', Current Cardiology Reports, vol. 9, pp. 493 - 498, http://dx.doi.org/10.1007/BF02938394

Skropeta D; Settasatian C; McMahon MR; Shearston K; Caiazza D; McGrath KC; Jin W; Rader DJ; Barter PJ; Rye KA, 2007, 'N-Glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-I-containing high density lipoproteins', Journal of Lipid Research, vol. 48, pp. 2047 - 2057, http://dx.doi.org/10.1194/jlr.M700248-JLR200

Deedwania P; Barter P; Carmena R; Fruchart JC; Grundy SM; Haffner S; Kastelein JJ; LaRosa JC; Schachner H; Shepherd J, 2006, 'Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study', Lancet, vol. 368, pp. 919 - 928, http://dx.doi.org/10.1016/S0140-6736(06)69292-1

Barter P, 2006, 'Options for therapeutic intervention: How effective are the different agents?', European Heart Journal, Supplement, vol. 8, http://dx.doi.org/10.1093/eurheartj/sul041

Barter P, 2006, 'Managing diabetic dyslipidaemia-beyond LDL-C:HDL-C and triglycerides', Atherosclerosis Supplements, vol. 7, pp. 17 - 21, http://dx.doi.org/10.1016/j.atherosclerosissup.2006.05.003

Waters DD; LaRosa JC; Barter P; Fruchart JC; Gotto AM; Carter R; Breazna A; Kastelein JJP; Grundy SM, 2006, 'Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study', Journal of the American College of Cardiology, vol. 48, pp. 1793 - 1799, http://dx.doi.org/10.1016/j.jacc.2006.07.041

Keech A; Simes RJ; Barter P; Horng MS, 2006, 'Fenofibrate and cardiovascular events in patients with type 2 diabetes: Commentary', Journal of Clinical Outcomes Management, vol. 13

Barter PJ; Ballantyne CM; Carmena R; Cabezas MC; Chapman MJ; Couture P; De Graaf J; Durrington PN; Faergeman O; Frohlich J, 2006, 'Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirty-person/ten-country panel', Journal of Internal Medicine, vol. 259, pp. 247 - 258, http://dx.doi.org/10.1111/j.1365-2796.2006.01616.x

Barter P; Kastelein J, 2006, 'Translating today's science into clinical practice', Atherosclerosis Supplements, vol. 7, pp. 1 - 2, http://dx.doi.org/10.1016/j.atherosclerosissup.2006.01.001

Keech A; Simes J; Barter P; Best J; Scott R; Taskinen MR, 2006, 'Correction to the FIELD study report', Lancet, vol. 368, pp. 1415, http://dx.doi.org/10.1016/S0140-6736(06)69594-9

Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S, 2006, 'Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating To New Targets (TNT) study', Diabetes Care, vol. 29, pp. 1220 - 1226, http://dx.doi.org/10.2337/dc05-2465

Barter PJ; Kastelein JJP, 2006, 'Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease', Journal of the American College of Cardiology, vol. 47, pp. 492 - 499, http://dx.doi.org/10.1016/j.jacc.2005.09.042

Keech A; Simes R; Barter P; Best J; Scott R; Taskinen MR, 2006, 'The FIELD study - Authors' reply', Lancet, vol. 367, pp. 1142 - 1143, http://dx.doi.org/10.1016/S0140-6736(06)68501-2

Kee P; Caiazza D; Rye KA; Barrett PHR; Morehouse LA; Barter PJ, 2006, 'Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: In vivo studies in rabbits', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, pp. 884 - 890, http://dx.doi.org/10.1161/01.ATV.0000201064.89581.35

Barter PJ; Rye KA, 2006, 'Cardioprotective properties of fibrates: Which fibrate, which patients, what mechanism?', Circulation, vol. 113, pp. 1553 - 1555, http://dx.doi.org/10.1161/CIRCULATIONAHA.105.620450

Barter P; Rye KA, 2006, 'Are we lowering LDL cholesterol sufficiently?', Nature Clinical Practice Cardiovascular Medicine, vol. 3, pp. 290 - 291, http://dx.doi.org/10.1038/ncpcardio0555

Nicholls SJ; Lundman P; Harmer JA; Cutri B; Griffiths KA; Rye KA; Barter PJ; Celermajer DS, 2006, 'Consumption of Saturated Fat Impairs the Anti-Inflammatory Properties of High-Density Lipoproteins and Endothelial Function', Journal of the American College of Cardiology, vol. 48, pp. 715 - 720, http://dx.doi.org/10.1016/j.jacc.2006.04.080

Hime NJ; Drew KJ; Wee K; Barter PJ; Rye KA, 2006, 'Formation of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbit', Journal of Lipid Research, vol. 47, pp. 115 - 122, http://dx.doi.org/10.1194/jlr.M500284-JLR200

Barter PJ; Rye KA; Gotto AM, 2006, 'The argument against the appropriateness of over-the-counter statins', Circulation, vol. 114, pp. 1315 - 1320, http://dx.doi.org/10.1161/CIRCULATIONAHA.105.604991

Barter PJ; Rye KA, 2006, 'Relationship between the concentration and antiatherogenic activity of high-density lipoproteins', Current Opinion in Lipidology, vol. 17, pp. 399 - 403, http://dx.doi.org/10.1097/01.mol.0000236365.40969.af

Barter PJ; Rye KA, 2006, 'Homocysteine and cardiovascular disease: Is HDL the link?', Circulation Research, vol. 99, pp. 565 - 566, http://dx.doi.org/10.1161/01.RES.0000243583.39694.1f

Gotto AM; Barter PJ; Rye KA, 2006, 'Over-the-counter statins are worth considering in primary prevention of cardiovascular disease', Circulation, vol. 114, pp. 1310 - 1314, http://dx.doi.org/10.1161/CIRCULATIONAHA.105.552257

Rye KA; Bright R; Psaltis M; Barter PJ, 2006, 'Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E', Journal of Lipid Research, vol. 47, pp. 1025 - 1036, http://dx.doi.org/10.1194/jlr.M500525-JLR200

Tso C; Martinic G; Fan WH; Rogers C; Rye KA; Barter PJ, 2006, 'High-density lipoproteins enhance progenitor-mediated endothelium repair in mice', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, pp. 1144 - 1149, http://dx.doi.org/10.1161/01.ATV.0000216600.37436.cf

LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJP; Shepherd J, 2005, 'Intensive lipid lowering with atorvastatin in patients with stable coronary disease', New England Journal of Medicine, vol. 352, pp. 1425 - 1435, http://dx.doi.org/10.1056/NEJMoa050461

Barter P, 2005, 'The inflammation: Lipoprotein cycle', Atherosclerosis Supplements, vol. 6, pp. 15 - 20, http://dx.doi.org/10.1016/j.atherosclerosissup.2005.02.004

Barter P, 2005, 'The realities of dyslipidaemia in metabolic syndrome and diabetes', British Journal of Diabetes and Vascular Disease, vol. 5

Barter PJ, 2005, 'Cardioprotective effects of high-density lipoproteins: The evidence strengthens', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, pp. 1305 - 1306, http://dx.doi.org/10.1161/01.ATV.0000172634.93210.5c

Barter PJ; Ballantyne CM, 2005, 'Discussion', International Journal of Clinical Practice, vol. 59, pp. 15 - 16, http://dx.doi.org/10.1111/j.1368-504X.2005.00539.x

Tonkin A; Barter P; Best J; Boyden A; Furler J; Hossack K; Sullivan D; Thompson P; Vale M; Cooper C, 2005, 'National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005.', Heart, lung & circulation, vol. 14, pp. 275 - 291, http://dx.doi.org/10.1016/j.hlc.2005.10.010

Yu Y; Wyszynski DF; Waterworth DM; Wilton SD; Barter PJ; Kesäniemi YA; Mahley RW; McPherson R; Waeber G; Bersot TP, 2005, 'Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia', Journal of Lipid Research, vol. 46, pp. 2202 - 2213, http://dx.doi.org/10.1194/jlr.M500137-JLR200

Barter PJ, 2005, 'Antiatherogenic properties of fibrates', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, pp. 1095 - 1096, http://dx.doi.org/10.1161/01.ATV.0000168895.21726.20

Barter PJ; O'Brien R; Watts GF; Zhu J; Hu D; Ho CC; Tomlinson B; Cheung BMY; Adam JMF; Tjokroprawiro A, 2005, 'Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: An Asian/Pacific consensus', British Journal of Diabetes and Vascular Disease, vol. 5

Stender S; Schuster H; Barter P; Watkins C; Kallend D, 2005, 'Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syn', Diabetes, Obesity and Metabolism, vol. 7, pp. 430 - 438, http://dx.doi.org/10.1111/j.1463-1326.2004.00450.x

Barter P, 2005, 'TNT - Atorvastatin 80 mg shows additional benefit', British Journal of Cardiology, vol. 12, pp. 95

Wyszynski DF; Waterworth DM; Barter PJ; Cohen J; Kesäniemi YA; Mahley RW; McPherson R; Waeber G; Bersot TP; Sharma SS, 2005, 'Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project)', American Journal of Cardiology, vol. 95, pp. 194 - 198, http://dx.doi.org/10.1016/j.amjcard.2004.08.091

Nicholls SJ; Rye KA; Barter PJ, 2005, 'High-density lipoproteins as therapeutic targets', Current Opinion in Lipidology, vol. 16, pp. 345 - 349, http://dx.doi.org/10.1097/01.mol.0000169356.58513.25

Nicholls SJ; Cutri B; Worthley SG; Kee P; Rye KA; Bao S; Barter PJ, 2005, 'Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, pp. 2416 - 2421, http://dx.doi.org/10.1161/01.ATV.0000184760.95957.d6

Nicholls SJ; Dusting GJ; Cutri B; Bao S; Drummond GR; Rye KA; Barter PJ, 2005, 'Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits', Circulation, vol. 111, pp. 1543 - 1550, http://dx.doi.org/10.1161/01.CIR.0000159351.95399.50

Keech AC; Scott R; Best J; Forder P; Taskinen MR; Simes J; Barter P; Colman P; d'Emden M; Davis T, 2005, 'Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]', Cardiovascular Diabetology, vol. 4, http://dx.doi.org/10.1186/1475-2840-4-13

Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A, 2004, 'Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study', American Heart Journal, vol. 147, pp. 705 - 712, http://dx.doi.org/10.1016/j.ahj.2003.10.004

Barter P, 2004, 'HDL: A recipe for longevity', Atherosclerosis Supplements, vol. 5, pp. 25 - 31, http://dx.doi.org/10.1016/j.atherosclerosissup.2004.03.003

Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glaszlou P; White H; Barter P; Tonkin A, 2004, 'Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: Results from the LIPID study', European Heart Journal, vol. 25, pp. 771 - 777, http://dx.doi.org/10.1016/j.ehj.2004.03.013

Carrick S; Ghersi D; Wilcken N; Simes J, 2004, 'Platinum containing regimens for metastatic breast cancer', The Cochrane database of systematic reviews, pp. CD003374

Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG, 2004, 'Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.', Atherosclerosis. Supplements, vol. 5, pp. 115 - 123, http://dx.doi.org/10.1016/j.atherosclerosissup.2004.08.032

Barter P, 2004, 'Metabolic abnormalities: High-density lipoproteins', Endocrinology and Metabolism Clinics of North America, vol. 33, pp. 393 - 403, http://dx.doi.org/10.1016/j.ecl.2004.03.006

Barter P, 2004, 'Global guidelines: National issues', International Congress Series, vol. 1262, pp. 184 - 187, http://dx.doi.org/10.1016/j.ics.2003.11.021

Barter PJ; Nicholls S; Rye KA; Anantharamaiah GM; Navab M; Fogelman AM, 2004, 'Antiinflammatory properties of HDL', Circulation Research, vol. 95, pp. 764 - 772, http://dx.doi.org/10.1161/01.RES.0000146094.59640.13

Rye KA; Barter PJ, 2004, 'Formation and Metabolism of Prebeta-Migrating, Lipid-Poor Apolipoprotein A-I', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, pp. 421 - 428, http://dx.doi.org/10.1161/01.ATV.0000104029.74961.f5

Hime NJ; Drew KJ; Hahn C; Barter PJ; Rye KA, 2004, 'Apolipoprotein E enhances hepatic lipase-mediated hydrolysis of reconstituted high-density lipoprotein phospholipid and triacylglycerol in an isoform-dependent manner', Biochemistry, vol. 43, pp. 12306 - 12314, http://dx.doi.org/10.1021/bi036305i

Barter P; Best J; Colman P; d'Emden M; Davis T; Drury P; Ehnholm C; Glasziou P; Hunt D; Keech A, 2004, 'The need for a large-scale trial of fibrate therapy in diabetes: The rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]', Cardiovascular Diabetology, vol. 3, http://dx.doi.org/10.1186/1475-2840-3-9

Wadham C; Albanese N; Roberts J; Wang L; Bagley CJ; Gamble JR; Rye KA; Barter PJ; Vadas MA; Xia P, 2004, 'High-Density Lipoproteins Neutralize C-Reactive Protein Proinflammatory Activity', Circulation, vol. 109, pp. 2116 - 2122, http://dx.doi.org/10.1161/01.CIR.0000127419.45975.26

Barter P, 2003, 'Reconsidering the value of fibrates: Lessons from the trials', British Journal of Diabetes and Vascular Disease, vol. 3, pp. 162 - 167, http://dx.doi.org/10.1177/14746514030030030201

Barter PJ; Brewer HB; Chapman MJ; Hennekens CH; Rader DJ; Tall AR, 2003, 'Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, pp. 160 - 167, http://dx.doi.org/10.1161/01.ATV.0000054658.91146.64

Barter P; Kastelein J; Nunn A; Hobbs R; Shepherd J; Ballantyne C; Brown V; Bruckert E; Carmena R; Davidson M, 2003, 'High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions', Atherosclerosis, vol. 168, pp. 195 - 211, http://dx.doi.org/10.1016/S0021-9150(03)00006-6

Rye KA; Wee K; Curtiss LK; Bonnet DJ; Barter PJ, 2003, 'Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation', Journal of Biological Chemistry, vol. 278, pp. 22530 - 22536, http://dx.doi.org/10.1074/jbc.M213250200

Duong MN; Psaltis M; Rader DJ; Marchadier D; Barter PJ; Rye KA, 2003, 'Evidence That Hepatic Lipase and Endothelial Lipase Have Different Substrate Specificities for High-Density Lipoprotein Phospholipids', Biochemistry, vol. 42, pp. 13778 - 13785, http://dx.doi.org/10.1021/bi034990n

Barter PJ, 2002, 'Coronary plaque regression: Role of low density lipoprotein-apheresis', Journal of the American College of Cardiology, vol. 40, pp. 228 - 230, http://dx.doi.org/10.1016/S0735-1097(02)01961-7

Packard C; Nunn A; Hobbs R; Barter P; Shepherd J; Kastelein J; Ballantyne C; Brown V; Bruckert E; Carmena R, 2002, 'High density Lipoprotein: Guardian of the vascular system?', International Journal of Clinical Practice, vol. 56, pp. 761 - 771

Barter P, 2002, 'Effects of inflammation on high-density lipoproteins', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, pp. 1062 - 1063, http://dx.doi.org/10.1161/01.ATV.0000024683.73431.99

Barter PJ, 2002, 'Gemfibrozil', Journal of Drug Evaluation: Cardiovascular Medicine, vol. 1, pp. 13 - 39

Barter PJ; Baker PW; Rye KA, 2002, 'Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells', Current Opinion in Lipidology, vol. 13, pp. 285 - 288, http://dx.doi.org/10.1097/00041433-200206000-00008

Kee P; Rye KA; Taylor JL; Barrett PHR; Barter PJ, 2002, 'Metabolism of ApoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: Studies in wild-type and hepatic lipase transgenic rabbits', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, pp. 1912 - 1917, http://dx.doi.org/10.1161/01.ATV.0000038485.94020.7F

Rye KA; Duong MN; Psaltis MK; Curtiss LK; Bonnet DJ; Stocker R; Barter PJ, 2002, 'Evidence that phospholipids play a key role in pre-β apoA-I formation and high-density lipoprotein remodeling', Biochemistry, vol. 41, pp. 12538 - 12545, http://dx.doi.org/10.1021/bi025998k

Barter P, 2001, 'Anti-atherogenic effects of fibrates in type 2 diabetes', Current Controlled Trials in Cardiovascular Medicine, vol. 2, pp. 218 - 220, http://dx.doi.org/10.1186/CVM-2-5-218

Watts GF; Dimmitt SB; Barter PJ, 2001, 'Normocholesterolaemic dyslipidaemia: Is there a role for fibrates?', Medical Journal of Australia, vol. 174, pp. 66 - 67

Tallis GA; Hamilton-Craig I; Watts GF; Barter PJ; Dimmitt SB, 2001, 'Normocholesterolaemic dyslipidaemia: Is there a role for fibrates? (multiple letters)', Medical Journal of Australia, vol. 174, pp. 610 - 611

Clay MA; Pyle DH; Rye KA; Vadas MA; Gamble JR; Barter PJ, 2001, 'Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins', Atherosclerosis, vol. 157, pp. 23 - 29, http://dx.doi.org/10.1016/S0021-9150(00)00659-6

Barter PJ; Rye KA, 2001, 'Cholesteryl ester transfer protein, high density lipoprotein and arterial disease', Current Opinion in Lipidology, vol. 12, pp. 377 - 382, http://dx.doi.org/10.1097/00041433-200108000-00002

Ashby D; Gamble J; Vadas M; Fidge N; Siggins S; Rye KA; Barter PJ, 2001, 'Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression', Atherosclerosis, vol. 154, pp. 113 - 121, http://dx.doi.org/10.1016/S0021-9150(00)00437-8

Hime NJ; Barter PJ; Rye KA, 2001, 'Evidence that apolipoprotein A-I facilitates hepatic lipase-mediated phospholipid hydrolysis in reconstituted HDL containing apolipoprotein A-II', Biochemistry, vol. 40, pp. 5496 - 5505, http://dx.doi.org/10.1021/bi0016671

MacMahon S; Neal B; Tzourio C; Rodgers A; Woodward M; Cutler J; Anderson C; Chalmers J; Ohkubo T; Bouser MG, 2001, 'Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack', Lancet, vol. 358, pp. 1033 - 1041, http://dx.doi.org/10.1016/S0140-6736(01)06178-5

Barter P, 2000, 'CETP and atherosclerosis', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, pp. 2029 - 2031, http://dx.doi.org/10.1161/01.ATV.20.9.2029

Barter PJ; O'Brien RC, 2000, 'Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice', Atherosclerosis, vol. 149, pp. 199 - 205, http://dx.doi.org/10.1016/S0021-9150(99)00402-5

Thompson GR; Barter PJ, 2000, 'Therapeutic approaches to reducing the LDL- and HDL-associated risks of coronary heart disease', Current Opinion in Lipidology, vol. 11, pp. 567 - 570, http://dx.doi.org/10.1097/00041433-200012000-00001

Baker PW; Rye KA; Gamble JR; Vadas MA; Barter PJ, 2000, 'Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression', Journal of Lipid Research, vol. 41, pp. 1261 - 1267

Clay MA; Pyle DH; Rye KA; Barter PJ, 2000, 'Formation of spherical, reconstituted high density lipoproteins containing both apolipoproteins A-I and A-II is mediated by lecithin:cholesterol acyltransferase', Journal of Biological Chemistry, vol. 275, pp. 9019 - 9025, http://dx.doi.org/10.1074/jbc.275.12.9019

Thompson GR; Barter PJ, 1999, 'Clinical lipidology at the end of the millennium', Current Opinion in Lipidology, vol. 10, pp. 521 - 526, http://dx.doi.org/10.1097/00041433-199912000-00007

Rye KA; Clay MA; Barter PJ, 1999, 'Remodelling of high density lipoproteins by plasma factors', Atherosclerosis, vol. 145, pp. 227 - 238, http://dx.doi.org/10.1016/S0021-9150(99)00150-1

Clay MA; Cehic DA; Pyle DH; Rye KA; Barter PJ, 1999, 'Formation of apolipoprotein-specific high-density lipoprotein particles from lipid-free apolipoproteins A-I and A-II', Biochemical Journal, vol. 337, pp. 445 - 451, http://dx.doi.org/10.1042/0264-6021:3370445

Baker PW; Rye KA; Gamble JR; Vadas MA; Barter PJ, 1999, 'Ability of reconstituted high density lipoproteins to inhibit cytokine- induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells', Journal of Lipid Research, vol. 40, pp. 345 - 353

Xia P; Vadas MA; Rye KA; Barter PJ; Gamble JR, 1999, 'High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against a therosclerosis by HDL', Journal of Biological Chemistry, vol. 274, pp. 33143 - 33147, http://dx.doi.org/10.1074/jbc.274.46.33143

Barter P, 1998, 'Atorvastatin: Answers to some important questions', Modern Medicine of Australia, vol. 41, pp. 114 - 115

Barter P, 1998, 'Cholesterol and coronary risk: Key issues in 1998', Modern Medicine of Australia, vol. 41, pp. 101 - 107

Contacos C; Barter PJ; Vrga L; Sullivan DR, 1998, 'Cholesteryl ester transfer in hypercholesterolaemia: Fasting and postprandial studies with and without pravastatin', Atherosclerosis, vol. 141, pp. 87 - 98, http://dx.doi.org/10.1016/S0021-9150(98)00151-8

James MJ; Van Reyk D; Rye KA; Dean RT; Cleland LG; Barter PJ; Jessup W, 1998, 'Low density lipoprotein of synovial fluid in inflammatory joint disease is mildly oxidized', Lipids, vol. 33, pp. 1115 - 1121, http://dx.doi.org/10.1007/s11745-998-0313-8

Rye KA; Jauhiainen M; Barter PJ; Ehnholm C, 1998, 'Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein', Journal of Lipid Research, vol. 39, pp. 613 - 622

Hime NJ; Barter PJ; Rye KA, 1998, 'The influence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol', Journal of Biological Chemistry, vol. 273, pp. 27191 - 27198, http://dx.doi.org/10.1074/jbc.273.42.27191

Ashby DT; Rye KA; Clay MA; Vadas MA; Gamble JR; Barter PJ, 1998, 'Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, pp. 1450 - 1455, http://dx.doi.org/10.1161/01.ATV.18.9.1450

Xia P; Gamble JR; Rye KA; Wang L; Hii CST; Cockerill P; Khew-Goodall Y; Bert AG; Barter PJ; Vadas MA, 1998, 'Tumor necrosis factor-α induces adhesion molecule expression through the sphingosine kinase pathway', Proceedings of the National Academy of Sciences of the United States of America, vol. 95, pp. 14196 - 14201, http://dx.doi.org/10.1073/pnas.95.24.14196

Tonkin A; Alyward P; Colquhoun D; Glasziou P; Harris P; Hunt D; Keech A; MacMahon S; Magnus P; Newel D, 1998, 'Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels', New England Journal of Medicine, vol. 339, pp. 1349 - 1357, http://dx.doi.org/10.1056/NEJM199811053391902

Vadas MA; Gamble JR; Rye K; Barter P, 1997, 'Regulation of leucocyte-endothelial interactions of special relevance to atherogenesis', Clinical and Experimental Pharmacology and Physiology, vol. 24, pp. a33 - a35

Rye KA; Hime NJ; Barter PJ, 1997, 'Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion', Journal of Biological Chemistry, vol. 272, pp. 3953 - 3960, http://dx.doi.org/10.1074/jbc.272.7.3953

Barter P; Sullivan D; Lloyd L; Fletcher P; Nestel P; Simons L; Butler J; Pitt A, 1997, 'NHF Guidelines on Managing Lipids: NHF Review of New Studies Confirms Importance of Managing Lipids', Current Therapeutics, vol. 38, pp. 35 - 39

Nestel P; Simons L; Barter P; Clifton P; Colquhoun D; Hamilton-Craig I; Sikaris K; Sullivan D, 1997, 'A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: Prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin', Atherosclerosis, vol. 129, pp. 231 - 239, http://dx.doi.org/10.1016/S0021-9150(96)06031-5

Clay MA; Barter PJ, 1996, 'Formation of new HDL particles from lipid-free apolipoprotein A-I', Journal of Lipid Research, vol. 37, pp. 1722 - 1732

Barter PJ; Rye KA, 1996, 'Molecular mechanisms of reverse cholesterol transport', Current Opinion in Lipidology, vol. 7, pp. 82 - 87, http://dx.doi.org/10.1097/00041433-199604000-00006

Barter PJ; Rye KA, 1996, 'High density lipoproteins and coronary heart disease', Atherosclerosis, vol. 121, pp. 1 - 12, http://dx.doi.org/10.1016/0021-9150(95)05675-0

Liang HQ; Rye KA; Barter PJ, 1996, 'Remodelling of reconstituted high density lipoproteins by lecithin:cholesterol acyltransferase', Journal of Lipid Research, vol. 37, pp. 1962 - 1979

Rye KA; Hime NJ; Barter PJ, 1996, 'The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteines', Journal of Biological Chemistry, vol. 271, pp. 4243 - 4250, http://dx.doi.org/10.1074/jbc.271.8.4243

Kee P; Bais R; Sobecki SK; Branford S; Rye KA; Barter PJ, 1996, 'Indirect sandwich enzyme-linked immunosorbent assay (ELISA) for plasma apolipoprotein E', Annals of Clinical Biochemistry, vol. 33, pp. 119 - 126, http://dx.doi.org/10.1177/000456329603300204

Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL, 1995, 'Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction', New England Journal of Medicine, vol. 332, pp. 1418 - 1424, http://dx.doi.org/10.1056/NEJM199505253322106

Barter PJ, 1995, 'Management of low HDL cholesterol.', Australian family physician, vol. 24

Cockerill GW; Rye KA; Gamble JR; Vadas MA; Barter PJ, 1995, 'High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, pp. 1987 - 1994, http://dx.doi.org/10.1161/01.ATV.15.11.1987

Liang HQ; Rye KA; Barter PJ, 1995, 'Cycling of apolipoprotein A-I between lipid-associated and lipid-free pools', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1257, pp. 31 - 37, http://dx.doi.org/10.1016/0005-2760(95)00055-H

Rye KA; Hime NJ; Barter PJ, 1995, 'The influence of cholesteryl ester transfer protein on the composition, size, and structure of spherical, reconstituted high density lipoproteins', Journal of Biological Chemistry, vol. 270, pp. 189 - 196, http://dx.doi.org/10.1074/jbc.270.1.189

Barter P, 1994, 'HDL cholesterol: To treat or not to treat?', Modern Medicine of Australia, vol. 37, pp. 43 - 45+47+49+51

Barter PJ, 1994, 'Overview', European Journal of Cardiovascular Prevention & Rehabilitation, vol. 1, pp. 193 - 196, http://dx.doi.org/10.1177/174182679400100301

Barter P, 1994, 'Cholesterol and cardiovascular disease: basic science', Australian and New Zealand Journal of Medicine, vol. 24, pp. 83 - 88, http://dx.doi.org/10.1111/j.1445-5994.1994.tb04441.x

Barbash GI; White HD; Modan M; Diaz R; Hampton JR; Heikkila J; Kristinsson A; Moulopoulos S; Paolasso EAC; Van Der Werf T, 1994, 'Outcome of Thrombolytic Therapy in Relation to Hospital Size and Invasive Cardiac Services', Archives of Internal Medicine, vol. 154, pp. 2237 - 2242, http://dx.doi.org/10.1001/archinte.1994.00420190141016

Barter P; Rye K, 1994, 'CHOLESTERYL ESTER TRANSFER PROTEIN: ITS ROLE IN PLASMA LIPID TRANSPORT', Clinical and Experimental Pharmacology and Physiology, vol. 21, pp. 663 - 672, http://dx.doi.org/10.1111/j.1440-1681.1994.tb02569.x

Rye KA; Barter PJ, 1994, 'The influence of apolipoproteins on the structure and function of spheroidal, reconstituted high density lipoproteins', Journal of Biological Chemistry, vol. 269, pp. 10298 - 10303

Barter PJ; Rye KA, 1994, 'High-density lipoproteins and coronary heart disease', European Journal of Cardiovascular Prevention & Rehabilitation, vol. 1, pp. 217 - 221, http://dx.doi.org/10.1177/174182679400100306

Liang HQ; Rye KA; Barter PJ, 1994, 'Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins', Journal of Lipid Research, vol. 35, pp. 1187 - 1199

Barter P; Rye KA, 1994, 'Erratum: Cholesteryl ester transfer protein: Its role in plasma lipid transport (Clinical and Experimental Pharmacology and Physiology, Vol. 21 (663-672))', Clinical and Experimental Pharmacology and Physiology, vol. 21, pp. 933

Contacos C; Barter PJ; Sullivan DR, 1993, 'Effect of pravastatin and ω-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 13, pp. 1755 - 1762, http://dx.doi.org/10.1161/01.ATV.13.12.1755

Barter P, 1993, 'High-density lipoproteins and reverse cholesterol transport', Current Opinion in Lipidology, vol. 4, pp. 210 - 217, http://dx.doi.org/10.1097/00041433-199306000-00006

Ebert DL; Warren RJ; Barter PJ; Mitchell A, 1993, 'Infusion of atherogenic lipoprotein particles increases hepatic lipase activity in the rabbit', Journal of Lipid Research, vol. 34, pp. 89 - 94

Rye KA; Garrety KH; Barter PJ, 1993, 'Preparation and characterization of spheroidal, reconstituted high-density lipoproteins with apolipoprotein A-I only or with apolipoprotein A-I and A-II', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1167, pp. 316 - 325, http://dx.doi.org/10.1016/0005-2760(93)90235-2

Barter PJ; Rajaram OV; Liang HQ; Rye KA, 1993, 'Relationship between the size and phospholipid content of low-density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1166, pp. 135 - 137, http://dx.doi.org/10.1016/0005-2760(93)90294-J

Newnham HH; Barter PJ, 1992, 'Changes in particle size of high density lipoproteins during incubation with very low density lipoproteins, cholesteryl ester transfer protein and lipoprotein lipase', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1125, pp. 297 - 304, http://dx.doi.org/10.1016/0005-2760(92)90059-5

Lagrost L; Barter PJ, 1992, 'Cholesteryl ester transfer protein promotes the association of HDL apolipoproteins A-I and A-II with LDL: potentiation by oleic acid', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1127, pp. 255 - 262, http://dx.doi.org/10.1016/0005-2760(92)90229-O

Clay MA; Newnham HH; Forte TM; Barter PI, 1992, 'Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1124, pp. 52 - 58, http://dx.doi.org/10.1016/0005-2760(92)90125-F

Rye KA; Garrety KH; Barter PJ, 1992, 'Changes in the size of reconstituted high density lipoproteins during incubation with cholesteryl ester transfer protein: The role of apolipoproteins', Journal of Lipid Research, vol. 33, pp. 215 - 224

Clay MA; Newnham HH; Barter PJ, 1991, 'Hepatic lipase promotes a loss of apolipoprotein A-I from triglyceride-enriched human high density lipoproteins during incubation in vitro', Arteriosclerosis and Thrombosis, vol. 11, pp. 415 - 422

Warren RJ; Ebert DL; Mitchell A; Barter PJ, 1991, 'Rabbit hepatic lipase cDNA sequence: Low activity is associated with low messenger RNA levels', Journal of Lipid Research, vol. 32, pp. 1333 - 1339

Meyer B; Kecorius E; Barter P; Fidge N; Tetaz T, 1991, 'Application of reversed-phase high-performance liquid chromatography to the separation of apolipoproteins A-IV, A-I and E from rat high-density lipoprotein', Journal of Chromatography A, vol. 540, pp. 386 - 391, http://dx.doi.org/10.1016/S0021-9673(01)88827-0

Barter PJ, 1991, 'ROLE OF NON‐ESTERIFIED FATTY ACIDS IN REGULATING PLASMA CHOLESTEROL TRANSPORT', Clinical and Experimental Pharmacology and Physiology, vol. 18, pp. 77 - 79, http://dx.doi.org/10.1111/j.1440-1681.1991.tb01410.x

Lagrost L; Barter PJ, 1991, 'Effects of various non-esterified fatty acids on the particle size redistribution of high density lipoproteins induced by the human cholesteryl ester transfer protein', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1082, pp. 204 - 210, http://dx.doi.org/10.1016/0005-2760(91)90195-N

Barter PJ; Chang LBF; Rajaram OV, 1991, 'Factors regulating the distribution of cholesterol between LDL and HDL', Advances in Experimental Medicine and Biology, vol. 285, pp. 59 - 64

Warren RJ; Ebert DL; Barter PJ; Mitchell A, 1991, 'The regulation of hepatic lipase and cholesteryl ester transfer protein activity in the cholesterol fed rabbit', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1086, pp. 354 - 358, http://dx.doi.org/10.1016/0005-2760(91)90181-G

BARTER PJ, 1991, 'High density lipoproteins and coronary heart disease', Australian and New Zealand Journal of Medicine, vol. 21, pp. 299 - 301, http://dx.doi.org/10.1111/j.1445-5994.1991.tb04693.x

Lagrost L; Barter PJ, 1991, 'Effects of various non-esterified fatty acids on the transfer of cholesteryl esters from HDL to LDL induced by the cholesteryl ester transfer protein', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1085, pp. 209 - 216, http://dx.doi.org/10.1016/0005-2760(91)90096-Z

Barter PJ, 1990, 'Enzymes involved in lipid and lipoprotein metabolism', Current Opinion in Lipidology, vol. 1, pp. 518 - 523, http://dx.doi.org/10.1097/00041433-199012000-00006

Newnham HH; Barter PJ, 1990, 'Synergistic effects of lipid transfers and hepatic lipase in the formation of very small high-density lipoproteins during incubation of human plasma', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1044, pp. 57 - 64, http://dx.doi.org/10.1016/0005-2760(90)90218-M

MACKINTOSH J; SIMES J; RAGHAVAN D; PEARSON B, 1990, 'Prostatic Cancer with Bone Metastases: Serum Alkaline Phosphatase (SAP) as a Predictor of Response and the Significance of the SAP “Flare”', British Journal of Urology, vol. 66, pp. 88 - 93, http://dx.doi.org/10.1111/j.1464-410X.1990.tb14871.x

Barter PJ; Chang LBF; Rajaram OV, 1990, 'Sodium oleate promotes a redistribution of cholesteryl esters from high to low density lipoproteins', Atherosclerosis, vol. 84, pp. 13 - 24, http://dx.doi.org/10.1016/0021-9150(90)90003-2

Barter PJ; Chang LBF; Rajaram OV, 1990, 'Sodium oleate dissociates the heteroexchange of cholesteryl esters and triacylglycerol between HDL and triacylglycerol-rich lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1047, pp. 294 - 297, http://dx.doi.org/10.1016/0005-2760(90)90529-7

Newnham HH; Hopkins GJ; Devlin S; Barter PJ, 1990, 'Lipoprotein lipase prevents the hepatic lipase-induced reduction in particle size of high density lipoproteins during incubation of human plasma', Atherosclerosis, vol. 82, pp. 167 - 176, http://dx.doi.org/10.1016/0021-9150(90)90037-J

Barter PJ; Chang LBF; Newnham HH; Rye KA; Rajaram OV, 1990, 'The interaction of cholesteryl ester transfer protein and unesterified fatty acids promotes a reduction in the particle size of high-density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1045, pp. 81 - 89, http://dx.doi.org/10.1016/0005-2760(90)90206-D

Clay MA; Rye KA; Barter PJ, 1990, 'Evidence in vitro that hepatic lipase reduces the concentration of apolipoprotein A-I in rabbit high-density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1044, pp. 50 - 56, http://dx.doi.org/10.1016/0005-2760(90)90217-L

Barter PJ, 1989, 'Abnormalities of cholesteryl ester transfer', Atherosclerosis VIII: proceedings of the 8th International Symposium on Atherosclerosis. ICS817, pp. 377 - 380

Hopkins GJ; Barter PJ, 1989, 'Apolipoprotein A-I inhibits transformation of high density lipoprotein subpopulations during incubation of human plasma', Atherosclerosis, vol. 75, pp. 73 - 82, http://dx.doi.org/10.1016/0021-9150(89)90209-8

Clay MA; Hopkins GJ; Ehnholm CP; Barter PJ, 1989, 'The rabbit as an animal model of hepatic lipase deficiency', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1002, pp. 173 - 181, http://dx.doi.org/10.1016/0005-2760(89)90284-1

Meyer BJ; Ha YC; Barter PJ, 1989, 'Effects of experimental hypothyroidism on the distribution of lipids and lipoproteins in the plasma of rats', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1004, pp. 73 - 79, http://dx.doi.org/10.1016/0005-2760(89)90215-4

Clifton PM; Barter PJ; Mackinnon AM, 1988, 'High density lipoprotein particle size distribution in subjects with obstructive jaundice', Journal of Lipid Research, vol. 29, pp. 121 - 135

National Heart Foundation Of Australia Coronary Thrombolysis Group, 1988, 'CORONARY THROMBOLYSIS AND MYOCARDIAL SALVAGE BY TISSUE PLASMINOGEN ACTIVATOR GIVEN UP TO 4 HOURS AFTER ONSET OF MYOCARDIAL INFARCTION', The Lancet, vol. 331, pp. 203 - 208, http://dx.doi.org/10.1016/S0140-6736(88)91063-X

Glasziou P; Hilden J; Simes J, 1988, 'Single Testing When Two Tests Are Available', Medical Decision Making, vol. 8, pp. 223, http://dx.doi.org/10.1177/0272989X8800800311

Barter PJ; Rajaram OV; Chang LBF; Rye KA; Gambert P; Lagrost L; Ehnholm C; Fidge NH, 1988, 'Isolation of a high-density-lipoprotein conversion factor from human plasma. A possible role of apoliprotein A-IV as its activator', Biochemical Journal, vol. 254, pp. 179 - 184, http://dx.doi.org/10.1042/bj2540179

Barter PJ; Hopkins GJ; Ha YC, 1987, 'The role of lipid transfer proteins in plasma lipoprotein metabolism', American Heart Journal, vol. 113, pp. 538 - 542, http://dx.doi.org/10.1016/0002-8703(87)90628-4

Barter PJ; Hopkins GJ; Rajaram OV, 1987, '6 Enzymes involved in plasma cholesterol transport', Bailliere's Clinical Endocrinology and Metabolism, vol. 1, pp. 623 - 638, http://dx.doi.org/10.1016/S0950-351X(87)80026-5

Clifton PM; MacKinnon AM; Barter PJ, 1987, 'Separation and characterization of high-density lipoprotein subpopulations by gel permeation chromatography', Journal of Chromatography B: Biomedical Sciences and Applications, vol. 414, pp. 25 - 34, http://dx.doi.org/10.1016/0378-4347(87)80021-X

Chea Ha Y; Barter PJ, 1986, 'Effects of sucrose feeding and injection of lipid transfer protein on rat plasma lipoproteins', Comparative Biochemistry and Physiology -- Part B: Biochemistry and, vol. 83, pp. 463 - 466, http://dx.doi.org/10.1016/0305-0491(86)90396-2

Rajaram OV; Barter PJ, 1986, 'Increases in the particle size of high-density lipoproteins induced by purified lecithin: cholesterol acyltransferase: effect of low-density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 877, pp. 406 - 414, http://dx.doi.org/10.1016/0005-2760(86)90206-7

Chang L; Clifton P; Barter P; Mackinnon, M.D. M, 1986, 'High density lipoprotein subpopulations in chronic liver disease', Hepatology, vol. 6, pp. 46 - 49, http://dx.doi.org/10.1002/hep.1840060109

Mackinnon M; Savage J; Wishart R; Barter P, 1986, 'Metabolism of high density lipoproteins by the perfused rabbit liver', Journal of Biological Chemistry, vol. 261, pp. 2548 - 2552

Hopkins GJ; Barter PJ, 1986, 'Role of triglyceride-rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteins', Journal of Lipid Research, vol. 27, pp. 1265 - 1277

Klein S; Simes J; Blackburn GL, 1986, 'Total parenteral nutrition and cancer clinical trials', Cancer, vol. 58, pp. 1378 - 1386, http://dx.doi.org/10.1002/1097-0142(19860915)58:6<1378::AID-CNCR2820580635>3.0.CO;2-S

Rye KA; Barter PJ, 1986, 'Changes in the size and density of human high-density lipoproteins promoted by a plasma-conversion factor', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 875, pp. 429 - 438, http://dx.doi.org/10.1016/0005-2760(86)90062-7

Malcolm MacKinnon A; Savage J; Gibson RA; Barter PJ, 1985, 'Secretion of cholesteryl ester-enriched very low density lipoproteins by the liver of cholesterol-fed rabbits', Atherosclerosis, vol. 54, pp. 145 - 155, http://dx.doi.org/10.1016/0021-9150(85)90174-1

Chang LBF; Hopkins GJ; Barter PJ, 1985, 'Particle size distribution of high density lipoproteins as a function of plasma triglyceride concentration in human subjects', Atherosclerosis, vol. 56, pp. 61 - 70, http://dx.doi.org/10.1016/0021-9150(85)90084-X

Clifton PM; Mackinnon AM; Barter PJ, 1985, 'Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction', Journal of Lipid Research, vol. 26, pp. 1389 - 1398

Ha YC; Chang LBF; Barter PJ, 1985, 'Effects of injecting exogenous lipid transfer protein into rats', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 833, pp. 203 - 210, http://dx.doi.org/10.1016/0005-2760(85)90191-2

Ha YC; Barter PJ, 1985, 'Rapid separation of plasma lipoproteins by gel permeation chromatography on agarose gel Superose 6B', Journal of Chromatography B: Biomedical Sciences and Applications, vol. 341, pp. 154 - 159, http://dx.doi.org/10.1016/S0378-4347(00)84020-7

Rajaram OV; Barter PJ, 1985, 'Reactivity of human lipoproteins with purified lecithin: cholesterol acyltransferase during incubations in vitro', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 835, pp. 41 - 49, http://dx.doi.org/10.1016/0005-2760(85)90028-1

Barter PJ; Hopkins GJ; Gorjatschko L, 1985, 'Lipoprotein substrates for plasma cholesterol esterification. Influence of particle size and composition of the high density lipoprotein subfraction 3', Atherosclerosis, vol. 58, pp. 97 - 107, http://dx.doi.org/10.1016/0021-9150(85)90058-9

Hopkins GJ; Chang LBF; Barter PJ, 1985, 'Role of lipid transfers in the formation of a subpopulation of small high density lipoproteins', Journal of Lipid Research, vol. 26, pp. 218 - 229

Barter PJ; Hopkins GJ; Gorjatschko L; Jones ME, 1984, 'Competitive inhibition of plasma cholesterol esterification by human high-density lipoprotein-subfraction 2', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 793, pp. 260 - 268, http://dx.doi.org/10.1016/0005-2760(84)90328-X

Ying Chea Ha; Chang LBF; Barter PJ, 1984, 'Incubation of human lipid transfer protein with plasma from normal-fed and cholesterol-fed rats: Effect on the distribution of constituents between lipoprotein fractions', Comparative Biochemistry and Physiology -- Part B: Biochemistry and, vol. 78, pp. 675 - 682, http://dx.doi.org/10.1016/0305-0491(84)90117-2

Greenspan EM; Peterson AP; Roth GJ; Gajwani BW; Gelber R; Simes J; Zelen M; Lessner HE; Mayer RJ; Ellenberg SS, 1984, 'Adjuvant Therapy for Colon Cancer', New England Journal of Medicine, vol. 311, pp. 410 - 411, http://dx.doi.org/10.1056/NEJM198408093110618

Moon EA; Mackinnon AM; Barter PJ, 1984, 'Appearance of serum amyloid protein in high-density lipoproteins of rabbits subjected to relatively mild stimuli', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 796, pp. 354 - 358, http://dx.doi.org/10.1016/0005-2760(84)90137-1

Barter PJ; Hopkins GJ; Gorjatschko L, 1984, 'Comparison of human plasma low- and high-density lipoproteins as substrates for lecithin: Cholesterol acyltransferase', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 792, pp. 1 - 5, http://dx.doi.org/10.1016/0005-2760(84)90274-1

Hopkins GJ; Barter PJ, 1984, 'Capacity of lipoproteins to act as substrates for lecithin:Cholesterol acyltransferase. Enhancement by pre-incubation with an artificial triacylglycerol emulsion', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 794, pp. 31 - 40, http://dx.doi.org/10.1016/0005-2760(84)90294-7

Abbey M; Calvert GD; Barter PJ, 1984, 'Changes in lipid and apolipoprotein composition of pig lipoproteins facilitated by rabbit lipid transfer protein', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 793, pp. 471 - 480, http://dx.doi.org/10.1016/0005-2760(84)90265-0

Abbey M; Savage JK; Mackinnon AM; Barter PJ; Calvert GD, 1984, 'Detection of lipid transfer protein activity in rabbit liver perfusate', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 793, pp. 481 - 484, http://dx.doi.org/10.1016/0005-2760(84)90266-2

Rye KA; Barter PJ, 1984, 'Evidence of the existence of a high-density lipoprotein transformation factor in pig and rabbit plasma', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 795, pp. 230 - 237, http://dx.doi.org/10.1016/0005-2760(84)90070-5

Barter PJ, 1983, 'Evidence that lecithin: Cholesterol acyltransferase acts on both high-density and low-density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 751, pp. 261 - 270, http://dx.doi.org/10.1016/0005-2760(83)90283-7

Hopkins GJ; Barter PJ, 1983, 'Role of esterified cholesterol transfers in the regulation of plasma cholesterol esterification', Atherosclerosis, vol. 49, pp. 177 - 185, http://dx.doi.org/10.1016/0021-9150(83)90195-8

Ha YC; Gorjatschko L; Barter PJ, 1983, 'Changes in the density distribution of pig high density lipoproteins during incubation in vitro. Influence of esterified cholesterol transfer activity', Atherosclerosis, vol. 48, pp. 253 - 263, http://dx.doi.org/10.1016/0021-9150(83)90043-6

Barter PJ; Hopkins GJ, 1983, 'Relative rates of incorporation of esterified cholesterol into human very low density lipoproteins and low density lipoproteins in vitro studies of two separate pathways', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 751, pp. 33 - 40, http://dx.doi.org/10.1016/0005-2760(83)90254-0

Barter PJ; Hopkins GJ; Gorjatschko L; Jones ME, 1982, 'A unified model of esterified cholesterol exchanges between human plasma lipoproteins', Atherosclerosis, vol. 44, pp. 27 - 40, http://dx.doi.org/10.1016/0021-9150(82)90050-8

Hopkins GJ; Barter PJ, 1982, 'An effect of very low density lipoproteins on the rate of cholesterol esterification in human plasma', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 712, pp. 152 - 160, http://dx.doi.org/10.1016/0005-2760(82)90097-2

Davis MW; Vaterlaws AL; Simes J; Torzillo P, 1982, 'Retinopathy in malaria.', Papua and New Guinea Medical Journal, vol. 25, pp. 19 - 22

Haa YC; Barter PJ, 1982, 'Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species', Comparative Biochemistry and Physiology -- Part B: Biochemistry and, vol. 71, pp. 265 - 269, http://dx.doi.org/10.1016/0305-0491(82)90252-8

Barter PJ; Gorjatschko L; Hopkins GJ, 1982, 'Comparison of different methods of isotopically labelling the esterified cholesterol in human high density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 710, pp. 349 - 358, http://dx.doi.org/10.1016/0005-2760(82)90118-7

Barter PJ; Hopkins GJ; Calvert GD, 1982, 'Transfers and exchanges of esterified cholesterol between plasma lipoproteins', Biochemical Journal, vol. 208, pp. 1 - 7, http://dx.doi.org/10.1042/bj2080001

Barter PJ; Hopkins GJ; Calvert GD, 1982, 'Pathways for the incorporation of esterified cholesterol into very low density and low density lipoproteins in plasma incubated in vitro', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 713, pp. 136 - 148, http://dx.doi.org/10.1016/0005-2760(82)90176-X

Hopkins GJ; Barter PJ, 1982, 'Dissociation of the in vitro transfers of esterified cholesterol and triglyceride between human lipoproteins', Metabolism, vol. 31, pp. 78 - 81, http://dx.doi.org/10.1016/0026-0495(82)90030-0

Ha YC; Calvert GD; McIntosh GH; Barter PJ, 1981, 'A physiologic role for the esterified cholesterol transfer protein: In vivo studies in rabbits and pigs', Metabolism, vol. 30, pp. 380 - 383, http://dx.doi.org/10.1016/0026-0495(81)90119-0

Williams DR; Barter PJ; Mackinnon AM, 1981, 'Serum lecithin: Cholesterol acyltransferase activity in the bile duct-ligated rat', Digestion, vol. 21, pp. 273 - 278, http://dx.doi.org/10.1159/000198574

Barter PJ; Ha YC; Calvert GD, 1981, 'Studies of esterified cholesterol in sub-fractions of plasma high density lipoproteins', Atherosclerosis, vol. 38, pp. 165 - 175, http://dx.doi.org/10.1016/0021-9150(81)90113-1

Rajaram OV; White GH; Barter PJ, 1980, 'Partial purification and characterization of a triacylglycerol-transfer protein from rabbit serum', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 617, pp. 383 - 392, http://dx.doi.org/10.1016/0005-2760(80)90004-1

Rajaram OV; Clark MG; Barter PJ, 1980, 'Differences in the metabolism of very-low-density lipoproteins by isolated beating-heart cells and the isolated perfused rat heart. Evidence for collagenase-released extracellular lipoprotein lipase', Biochemical Journal, vol. 186, pp. 431 - 438, http://dx.doi.org/10.1042/bj1860431

Rajaram OV; Barter PJ, 1980, 'Influence of lipoprotein concentration on the exchanges of triacylglycerol between rabbit plasma low density and high density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 620, pp. 483 - 488, http://dx.doi.org/10.1016/0005-2760(80)90140-X

Barter PJ; Gorjatschko L; Calvert GD, 1980, 'Net mass transfer of esterified cholesterol from human low density lipoproteins to very low density lipoproteins incubated in vitro', Biochimica et Biophysica Acta - Lipids and Lipid Metabolism, vol. 619, pp. 436 - 439, http://dx.doi.org/10.1016/0005-2760(80)90095-8

Hopkins GJ; Barter PJ, 1980, 'Transfers of esterified cholesterol and triglyceride between high density and very low density lipoproteins: In vitro studies of rabbits and humans', Metabolism, vol. 29, pp. 546 - 550, http://dx.doi.org/10.1016/0026-0495(80)90080-3

Barter PJ; Jones ME, 1980, 'Kinetic studies of the transfer of esterified cholesterol between human plasma low and high density lipoproteins', Journal of Lipid Research, vol. 21, pp. 238 - 249

Lally JI; Barter PJ, 1979, 'The in vivo metabolism of esterified cholesterol in the plasma high-density lipoproteins of rabbits', The Journal of Laboratory and Clinical Medicine, vol. 93, pp. 570 - 582

Barter PJ; Lally JI, 1979, 'The metabolism of esterified cholesterol in rabbit plasma low density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 572, pp. 510 - 518, http://dx.doi.org/10.1016/0005-2760(79)90158-9

Barter PJ; Jones ME, 1979, 'Rate of exchange of esterified cholesterol between human plasma low and high density lipoproteins', Atherosclerosis, vol. 34, pp. 67 - 74, http://dx.doi.org/10.1016/0021-9150(79)90107-2

Barter PJ; Gooden JM; Rajaram OV, 1979, 'Species differences in the activity of a serum triglyceride transferring factor', Atherosclerosis, vol. 33, pp. 165 - 169, http://dx.doi.org/10.1016/0021-9150(79)90113-8

Barter PJ; Lally JI; Wattchow D, 1979, 'Metabolism of triglyceride in rabbit plasma low and high density lipoproteins: Studies in vivo and in vitro', Metabolism, vol. 28, pp. 614 - 618, http://dx.doi.org/10.1016/0026-0495(79)90012-X

Ha YC; Calvert GD; Barter PJ, 1979, 'In vivo metabolism of esterified cholesterol and apoproteins in rabbit plasma low density lipoproteins', Atherosclerosis, vol. 34, pp. 451 - 455, http://dx.doi.org/10.1016/0021-9150(79)90069-8

Barter PJ; Lally JI, 1979, 'In vitro exchanges of esterified cholesterol between serum lipoprotein fractions: Studies of humans and rabbits', Metabolism, vol. 28, pp. 230 - 236, http://dx.doi.org/10.1016/0026-0495(79)90068-4

Wood PR; Simes RJ; Nelson DS, 1979, 'Activity of mouse macrophages purified by adherence to, and removal from, a plastic surface', Journal of Immunological Methods, vol. 28, pp. 117 - 124, http://dx.doi.org/10.1016/0022-1759(79)90333-8

Barter PJ; Lally JI, 1978, 'The activity of an esterified cholesterol transferring factor in human and rat serum', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 531, pp. 233 - 236, http://dx.doi.org/10.1016/0005-2760(78)90147-9

Barter PJ; I.Lally J, 1978, 'Metabolism of esterified cholesterol in the plasma very low density lipoproteins of the rabbit. Studies in vivo and in vitro', Atherosclerosis, vol. 31, pp. 355 - 364, http://dx.doi.org/10.1016/0021-9150(78)90070-9

Barter P; Faergeman O; Havel RJ, 1977, 'Metabolism of cholesteryl esters of very low density lipoproteins in the guinea pig', Metabolism, vol. 26, pp. 615 - 622, http://dx.doi.org/10.1016/0026-0495(77)90083-X

Barter PJ; Connor WE, 1976, 'The transport of esterified cholesterol in plasma high density lipoproteins of human subjects: a mathematical model', The Journal of Laboratory and Clinical Medicine, vol. 88, pp. 627 - 639

Barter PJ; Connor WE, 1975, 'The transport of triglyceride in the high-density lipoproteins of human plasma', The Journal of Laboratory and Clinical Medicine, vol. 85, pp. 260 - 272

Barter PJ, 1974, 'Origin of esterified cholesterol transported in the very low density lipoproteins of human plasma', Journal of Lipid Research, vol. 15, pp. 11 - 19

Barter PJ; Connor WE; Spector AA; Armstrong M; Connor SL; Newman MA, 1974, 'Lowering of serum cholesterol and triglyceride by para aminosalicylic acid in hyperlipoproteinemia. Studies in patients with types II A and II B', Annals of Internal Medicine, vol. 81, pp. 619 - 624, http://dx.doi.org/10.7326/0003-4819-81-5-619

Barter PJ, 1974, 'Production of plasma esterified cholesterol in lean, normotriglyceridemic humans.', Journal of Lipid Research, vol. 15, pp. 234 - 242

Nestel PJ; Barter PJ, 1973, 'Triglyceride clearance during diets rich in carbohydrate or fats.', American Journal of Clinical Nutrition, vol. 26, pp. 241 - 245

Barter PJ; Nestel PJ, 1973, 'Precursors of plasma triglyceride fatty acids in obesity', Metabolism, vol. 22, pp. 779 - 785, http://dx.doi.org/10.1016/0026-0495(73)90048-6

Barter PJ; Nestel PJ, 1972, 'Precursor-product relationship between pools of very low density lipoprotein triglyceride.', The Journal of clinical investigation, vol. 51, pp. 174 - 180, http://dx.doi.org/10.1172/JCI106789

Barter PJ; Nestel PJ, 1972, 'Plasma free fatty acid transport during prolonged glucose consumption and its relationship to plasma triglyceride fatty acids in man', Journal of Lipid Research, vol. 13, pp. 483 - 490

Barter PJ; Nestel PJ; Carroll KF, 1972, 'Precursors of plasma triglyceride fatty acid in humans. Effects of glucose consumption, clofibrate administration, and alcoholic fatty liver', Metabolism, vol. 21, pp. 117 - 124, http://dx.doi.org/10.1016/0026-0495(72)90063-7

Nestel PJ; Barter P, 1971, 'Metabolism of palmitic and linoleic acids in man: differences in turnover and conversion to glycerides.', Clinical science, vol. 40, pp. 345 - 350

Barter PJ; Carroll KF; Nestel PJ, 1971, 'Diurnal fluctuations in triglyceride, free fatty acids, and insulin during sucrose consumption and insulin infusion in man.', The Journal of clinical investigation, vol. 50, pp. 583 - 591, http://dx.doi.org/10.1172/JCI106528

Barter PJ; Nestel PJ, 1970, 'The distribution of triglyceride in subclasses of very low density plasma lipoproteins', The Journal of Laboratory and Clinical Medicine, vol. 76, pp. 925 - 932

Palmer MK; Nicholls SJ; Lundman P; Barter PJ; Karlson BW, 2015, 'Estimating the reduction in 10-year atherosclerotic cardiovascular disease risk with statin therapy: a VOYAGER meta-analysis', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, London, ENGLAND, pp. 1151 - 1151, presented at Congress of the European-Society-of-Cardiology (ESC), London, ENGLAND, 29 August - 02 September 2015, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361205107481&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2014, 'Impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridaemia: a VOYAGER meta-analysis', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, Barcelona, SPAIN, pp. 217 - 217, presented at Annual Meeting of the European-Society-of-Cardiology (ESC), Barcelona, SPAIN, 30 August - 03 September 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343001301161&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2014, 'VARIABILITY OF LDL-C RESPONSE WITH DIFFERENT DOSES OF SIMVASTATIN, ATORVASTATIN AND ROSUVASTATIN: RESULTS FROM VOYAGER', in ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, Spanish Soc Atherosclerosis, Madrid, SPAIN, pp. E295 - E295, presented at 82nd Congress of the European-Atherosclerosis-Society (EAS), Spanish Soc Atherosclerosis, Madrid, SPAIN, 31 May - 03 June 2014, http://dx.doi.org/10.1016/j.atherosclerosis.2014.05.889

Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2014, 'To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in the four statin benefit groups identified by the ACC/AHA 2013 guidelines? A VOYAGER meta-analysis', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, Barcelona, SPAIN, pp. 679 - 679, presented at Annual Meeting of the European-Society-of-Cardiology (ESC), Barcelona, SPAIN, 30 August - 03 September 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343001304110&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2014, 'DOSES OF ROSUVASTATIN, ATORVASTATIN AND SIMVASTATIN INDUCING AN EQUIPOTENT EFFECT ON LDL-C: RESULTS FROM THE VOYAGER META-ANALYSIS', in ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, Spanish Soc Atherosclerosis, Madrid, SPAIN, pp. E35 - E35, presented at 82nd Congress of the European-Atherosclerosis-Society (EAS), Spanish Soc Atherosclerosis, Madrid, SPAIN, 31 May - 03 June 2014, http://dx.doi.org/10.1016/j.atherosclerosis.2014.05.071

Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2014, 'ATTAINMENT OF THE ANTICIPATED >=50% REDUCTION IN LDL-C IN THE FOUR ACC/AHA GUIDELINES STATIN BENEFIT GROUPS: A VOYAGER META-ANALYSIS', in ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, Spanish Soc Atherosclerosis, Madrid, SPAIN, pp. E11 - E12, presented at 82nd Congress of the European-Atherosclerosis-Society (EAS), Spanish Soc Atherosclerosis, Madrid, SPAIN, 31 May - 03 June 2014, http://dx.doi.org/10.1016/j.atherosclerosis.2014.05.003

Fryirs MA; Barter PJ; Appavoo M; Tuch B; Tabet F; Heater AK; Rye KA, 2009, 'High Density Lipoproteins Increase the Insulin Secretory Capacity of Pancreatic beta-Cells', in DIABETES, AMER DIABETES ASSOC, New Orleans, LA, pp. A426 - A426, presented at 69th Annual Meeting of the American-Diabetes-Association, New Orleans, LA, 05 - 09 June 2009, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000266352602394&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Barter PJ; Rye KA, 2006, 'The rationale for using apoA-I as a clinical marker of cardiovascular risk', in Journal of Internal Medicine, pp. 447 - 454, http://dx.doi.org/10.1111/j.1365-2796.2006.01647.x

Barter P, 2005, 'The role of HDL-cholesterol in preventing atherosclerotic disease', in European Heart Journal, Supplement, http://dx.doi.org/10.1093/eurheartj/sui036

Barter P; Hanefeld M, 2005, 'Dyslipidaemia and the metabolic syndrome: Critical issues in improving CVD risk reduction', in British Journal of Diabetes and Vascular Disease

Barter P, 2004, 'Is high-density lipoprotein the protector of the cardiovascular system?', in European Heart Journal, Supplement, http://dx.doi.org/10.1016/j.ehjsup.2004.01.005

Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG; Davidson MH, 2003, 'Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals', in American Journal of Cardiology, pp. 11 - 17, http://dx.doi.org/10.1016/S0002-9149(03)00004-3

Rader DJ; Davidson MH; Caplan RJ; Pears JS; Stein EA; Shepherd J; Barter P; Hobbs R, 2003, 'Lipid and apolipoprotein ratios: Association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin', in American Journal of Cardiology, pp. 20 - 23, http://dx.doi.org/10.1016/S0002-9149(03)00005-5

Ballantyne CM; Stein EA; Paoletti R; Southworth H; Blasetto JW; Barter P; Rader DJ, 2003, 'Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome', in American Journal of Cardiology, pp. 25 - 27, http://dx.doi.org/10.1016/S0002-9149(03)00006-7

Barter P, 2003, 'Lipids, inflammation and CVD - Understanding the basics to break the atherosclerosis cycle: Introduction', in International Journal of Clinical Practice, Supplement, pp. 2 - 4

Barter PJ, 2003, 'In a modern world, atherosclerosis is an almost evolutionary certuinty: Introduction', in International Journal of Clinical Practice, Supplement, pp. 2

Barter PJ, 2002, 'Hugh Sinclair Lecture: The regulation and remodelling of HDL by plasma factors', in Atherosclerosis Supplements, pp. 39 - 47, http://dx.doi.org/10.1016/S1567-5688(02)00041-7

Shepherd J; Barter P, 2002, 'Lipid-lowering - Translating evidence into benefits', in Atherosclerosis Supplements, pp. 1 - 3, http://dx.doi.org/10.1016/S1567-5688(01)00015-0

Barter P, 2002, 'Treatment of dyslipidaemia in high-risk patients: Too little, too late', in International Journal of Clinical Practice, Supplement, pp. 15 - 19

Barter PJ; Sacks FM, 2001, 'Threshold level or not for low-density lipoprotein cholesterol', in American Journal of Managed Care

Lacko AG; Barter P; Ehnholm C; Van Tol A, 2000, 'International symposium on basic aspects of HDL metabolism and disease prevention', in Journal of Lipid Research, pp. 1695 - 1699

Barter P, 2000, 'Cholesterol management: How to implement best practice', in European Heart Journal, Supplement

Barter PJ, 2000, 'Treating to target with statins', in Atherosclerosis Supplements, pp. 21 - 25, http://dx.doi.org/10.1016/S0021-9150(00)00564-5

Barter P, 1999, 'The National Heart Foundation's research program', in Asia Pacific Heart Journal, pp. 178 - 180, http://dx.doi.org/10.1016/S1328-0163(99)90058-1

Barter PJ, 1997, 'Inhibition of endothelial cell adhesion molecule expression by high density lipoproteins', in Clinical and Experimental Pharmacology and Physiology, pp. 286 - 287, http://dx.doi.org/10.1111/j.1440-1681.1997.tb01821.x

Stuart-Harris R; Dalley D; Bell DR; Levi J; Simes RJ; Wiltshaw E, 1993, 'Ifosfamide combination regimens for soft-tissue sarcoma', in Cancer Chemotherapy and Pharmacology

Beilin L; Heller R; Butler J; Simes J; Calvert D; Birkett D; Sullivan D; Mudge P; Kniha E; Thompson P, 1992, 'The management of hyperlipidaemia: A consensus statement', in Medical Journal of Australia

Barter PJ; Chang LBF; Newnham HH; Rye KA; Rajaram OV, 1990, 'Roles of lecithin: Cholesterol acyltransferase, lipid transfer proteins and nonesterified fatty acids in plasma cholesterol transport', in Journal of Drug Development, Supplement, pp. 85 - 89

Barter PJ, 1977, 'POPULATION SCREENING FOR PLASMA LIPIDS', in Australian and New Zealand Journal of Medicine, pp. 675 - 675, http://dx.doi.org/10.1111/j.1445-5994.1977.tb02355.x

Wu BJ; Shrestha S; Ong KL; Johns DG; Barter PJ; Rye K-A, 2012, 'Effects of Cholesteryl Ester Transfer Protein Inhibition on Endothelial Repair and Function', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, Vol. 126, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208885001039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ong KL; Allison MA; Cheung BMY; Wu BJ; Barter PJ; Rye K-A, 2012, 'C-Reactive Protein Trends and Associations with Total Mortality in United States Adults between 1999-2010', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, Vol. 126, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208885000078&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ong KL; Rye K-A; O'Connell R; Jenkins AJ; Brown C; Xu A; Sullivan DR; Barter PJ; Keech AC, 2012, 'Long-term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-binding Protein 4 in Subjects With Type 2 Diabetes', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, Vol. 126, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208885001409&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ong KL; Wu BJ; Cheung BMY; Barter PJ; Rye K-A, 2011, 'Arthritis: Its Prevalence, Risk Factors, and Association with Cardiovascular Diseases in the United States National Health and Nutrition Examination Survey 1999-2008', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, Vol. 124, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000299738703116&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1